{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "01",
                "@timestamp": "2023-06-01T11:41:32.000032-04:00",
                "@year": "2023",
                "@month": "06"
            },
            "ait:date-sort": {
                "@day": "01",
                "@year": "2023",
                "@month": "01"
            }
        },
        "xocs:meta": {"xocs:funding-list": {
            "@pui-match": "primary",
            "@has-funding-info": "1",
            "xocs:funding": [
                {
                    "xocs:funding-agency-matched-string": "National Institutes of Health",
                    "xocs:funding-agency-acronym": "NIH",
                    "xocs:funding-agency": "National Institutes of Health",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100000002",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "National Cancer Institute",
                    "xocs:funding-agency-acronym": "NCI",
                    "xocs:funding-agency": "National Cancer Institute",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100000054",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                }
            ],
            "xocs:funding-addon-generated-timestamp": "2023-03-03T05:51:03.494Z",
            "xocs:funding-text": "K Nath and MA Perales are supported by the Memorial Sloan Kettering Cancer Center Core Grant (P30 CA008748) from the National Institutes of Health/National Cancer Institute. MA Perales reports honoraria from Abbvie, Allovir, Astellas, Bristol-Myers Squibb, Caribou Biosciences, Celgene, Equilium, Exevir, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Novartis, Nektar Therapeutics, Omeros, OrcaBio, Takeda, and VectivBio AG, Vor Biopharma. MA Perales serves on DSMBs for Cidara Therapeutics, Medigene, Sellas Life Sciences, and Servier, and the scientific advisory board of NexImmune. MA Perales has ownership interests in NexImmune and Omeros. MA Perales has received institutional research support for clinical trials from Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",
            "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"
        }},
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60009343",
                            "@country": "usa",
                            "city": "New York",
                            "organization": [
                                {"$": "Cellular Therapy Service"},
                                {"$": "Department of Medicine"},
                                {"$": "Memorial Sloan Kettering Cancer Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "60009343",
                                "@dptid": "109501192"
                            },
                            "state": "NY",
                            "@affiliation-instance-id": "OB2BibRecID-946176707-c138d20568dac9eeb4df4362ec9777f0-1",
                            "ce:source-text": "Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA",
                            "@dptid": "109501192"
                        },
                        "author": [{
                            "ce:given-name": "Karthik",
                            "preferred-name": {
                                "ce:given-name": "Karthik",
                                "ce:initials": "K.",
                                "ce:surname": "Nath",
                                "ce:indexed-name": "Nath K."
                            },
                            "@author-instance-id": "OB2BibRecID-946176707-1fe176469a442dab77d0f15c6655ccb6-1",
                            "@seq": "1",
                            "ce:initials": "K.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Nath",
                            "@auid": "57211201733",
                            "@orcid": "0000-0002-3881-5681",
                            "ce:indexed-name": "Nath K."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60002620",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Division of Hematology and Center of Excellence in Translational Hematology"},
                                {"$": "Faculty of Medicine"},
                                {"$": "Chulalongkorn University"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60002620",
                                    "@dptid": "129117147"
                                },
                                {"@afid": "60028190"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-946176707-05f19e18c6325a753a217ec1305fe959-1",
                            "ce:source-text": "Division of Hematology and Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand",
                            "@dptid": "129117147"
                        },
                        "author": [{
                            "ce:given-name": "Kitsada",
                            "preferred-name": {
                                "ce:given-name": "Kitsada",
                                "ce:initials": "K.",
                                "ce:surname": "Wudhikarn",
                                "ce:indexed-name": "Wudhikarn K."
                            },
                            "@author-instance-id": "OB2BibRecID-946176707-9c6f009fe7bf06b6823278b25caf9b07-1",
                            "@seq": "2",
                            "ce:initials": "K.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Wudhikarn",
                            "@auid": "37091810400",
                            "@orcid": "0000-0001-9528-8681",
                            "ce:indexed-name": "Wudhikarn K."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Spain",
                            "@afid": "60033237",
                            "@country": "esp",
                            "city": "Madrid",
                            "organization": [
                                {"$": "Division of Hematology and Hemotherapy"},
                                {"$": "Hospital General Universitario Gregorio Marañón"}
                            ],
                            "affiliation-id": {
                                "@afid": "60033237",
                                "@dptid": "115130570"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-946176707-df56bf42da9c755891f02f397572d85e-1",
                            "ce:source-text": "Division of Hematology and Hemotherapy, Hospital General Universitario Gregorio Marañón, Madrid, Spain",
                            "@dptid": "115130570"
                        },
                        "author": [{
                            "ce:given-name": "Ana",
                            "preferred-name": {
                                "ce:given-name": "Ana",
                                "ce:initials": "A.",
                                "ce:surname": "Alarcon Tomas",
                                "ce:indexed-name": "Alarcon Tomas A."
                            },
                            "@author-instance-id": "OB2BibRecID-946176707-00dabb50c08e8331fa53c353ff83a6e4-1",
                            "@seq": "3",
                            "ce:initials": "A.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Alarcon Tomas",
                            "@auid": "57202007577",
                            "ce:indexed-name": "Alarcon Tomas A."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60009343",
                            "@country": "usa",
                            "city": "New York",
                            "organization": [
                                {"$": "Adult Bone Marrow Transplantation Service"},
                                {"$": "Department of Medicine"},
                                {"$": "Memorial Sloan Kettering Cancer Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "60009343",
                                "@dptid": "109501192"
                            },
                            "state": "NY",
                            "@affiliation-instance-id": "OB2BibRecID-946176707-55974a7cafbe00e9304087641aeccd8d-1",
                            "ce:source-text": "Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA",
                            "@dptid": "109501192"
                        },
                        "author": [{
                            "ce:given-name": "Miguel-Angel",
                            "preferred-name": {
                                "ce:given-name": "Miguel Angel",
                                "ce:initials": "M.A.",
                                "ce:surname": "Perales",
                                "ce:indexed-name": "Perales M.A."
                            },
                            "@author-instance-id": "OB2BibRecID-946176707-db2fee2af8da61fb547b03932a25ca3a-1",
                            "@seq": "4",
                            "ce:initials": "M.-A.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Perales",
                            "@auid": "6701893624",
                            "ce:indexed-name": "Perales M.-A."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60007997",
                            "@country": "usa",
                            "city": "New York",
                            "organization": [
                                {"$": "Department of Medicine"},
                                {"$": "Weill Cornell Medical College"}
                            ],
                            "affiliation-id": {
                                "@afid": "60007997",
                                "@dptid": "112748380"
                            },
                            "state": "NY",
                            "@affiliation-instance-id": "OB2BibRecID-946176707-04a98a63dc4139712fbef1f65dd67764-1",
                            "ce:source-text": "Department of Medicine, Weill Cornell Medical College, New York, NY, USA",
                            "@dptid": "112748380"
                        },
                        "author": [{
                            "ce:given-name": "Miguel-Angel",
                            "preferred-name": {
                                "ce:given-name": "Miguel Angel",
                                "ce:initials": "M.A.",
                                "ce:surname": "Perales",
                                "ce:indexed-name": "Perales M.A."
                            },
                            "@author-instance-id": "OB2BibRecID-946176707-db2fee2af8da61fb547b03932a25ca3a-1",
                            "@seq": "4",
                            "ce:initials": "M.-A.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Perales",
                            "@auid": "6701893624",
                            "ce:indexed-name": "Perales M.-A."
                        }]
                    }
                ],
                "citation-title": "Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma",
                "abstracts": "© 2023 Informa UK Limited, trading as Taylor & Francis Group.Introduction: CD19-directed chimeric antigen receptor (CAR) T-cell therapy is a highly effective therapy for patients with relapsed/refractory large B-cell lymphoma (LBCL) and three CD19 CAR T-cell products (axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel) are currently approved for this indication. Despite the clinical benefit of CD19 directed CAR T-cell therapy, this treatment is associated with significant morbidity from treatment-emergent toxicities. Areas covered: This Review discusses the safety considerations of axicabtagene ciloleucel in patients with LBCL. This includes discussion of the frequently observed immune-mediated toxicities of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Additionally, we review CAR T-cell therapy related cytopenias, infection, organ dysfunction and the more recently described hemophagocytic lymphohistiocytosis. Expert Opinion: A thorough understanding of the toxicities associated with CD19-directed CAR T-cell therapy will facilitate the optimal selection of patients for this therapy. Furthermore, knowledge of preventative measures of CAR T-cell related complications, and early recognition and appropriate intervention will lead to the safe administration of these therapies, and ultimately improved outcomes for our patients.",
                "correspondence": {
                    "affiliation": {
                        "country": "United States",
                        "address-part": "530 East 74th Street, Box 59",
                        "postal-code": "10021",
                        "@country": "usa",
                        "city": "New York",
                        "organization": [
                            {"$": "Adult BMT Service"},
                            {"$": "Memorial Sloan Kettering Cancer Center"}
                        ],
                        "state": "NY",
                        "@affiliation-instance-id": "OB2BibRecID-946176707-0c05433698df2ce3f95cac47a6b41a16-1",
                        "ce:source-text": "Adult BMT Service, Memorial Sloan Kettering Cancer Center, 530 East 74th Street, Box 59, New York, NY, 10021, USA"
                    },
                    "person": {
                        "ce:given-name": "Miguel-Angel",
                        "@author-instance-id": "OB2BibRecID-946176707-6c8aac8ad49f6307729d4d87020b298a-1",
                        "ce:initials": "M.-A.",
                        "ce:surname": "Perales",
                        "ce:indexed-name": "Perales M.-A."
                    }
                },
                "citation-info": {
                    "author-keywords": {"author-keyword": [
                        {
                            "$": "Axicabtagene ciloleucel",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "chimeric antigen receptor (CAR) T-cell therapy",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "cytokine release syndrome (CRS)",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "immune effector cell-associated neurotoxicity syndrome (ICANS)",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "large B-cell lymphoma (LBCL)",
                            "@xml:lang": "eng",
                            "@original": "y"
                        }
                    ]},
                    "citation-type": {"@code": "ar"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "website": {"ce:e-address": {
                        "$": "https://www.tandfonline.com/loi/ieds20",
                        "@type": "email"
                    }},
                    "translated-sourcetitle": {
                        "$": "Expert Opinion on Drug Safety",
                        "@xml:lang": "eng"
                    },
                    "volisspag": {
                        "voliss": {
                            "@volume": "22",
                            "@issue": "1"
                        },
                        "pagerange": {
                            "@first": "5",
                            "@last": "15"
                        }
                    },
                    "@type": "j",
                    "sourcetitle": "Expert Opinion on Drug Safety",
                    "publicationdate": {
                        "year": "2023",
                        "date-text": {
                            "@xfab-added": "true",
                            "$": "2023"
                        }
                    },
                    "codencode": "EODSA",
                    "sourcetitle-abbrev": "Expert Opin. Drug Saf.",
                    "@country": "gbr",
                    "issn": [
                        {
                            "$": "1744764X",
                            "@type": "electronic"
                        },
                        {
                            "$": "14740338",
                            "@type": "print"
                        }
                    ],
                    "publicationyear": {"@first": "2023"},
                    "publisher": {"publishername": "Taylor and Francis Ltd."},
                    "@srcid": "21349"
                },
                "enhancement": {
                    "classificationgroup": {"classifications": [
                        {
                            "@type": "EMCLASS",
                            "classification": [
                                {
                                    "classification-code": "16",
                                    "classification-description": "Cancer"
                                },
                                {
                                    "classification-code": "25",
                                    "classification-description": "Hematology"
                                },
                                {
                                    "classification-code": "26",
                                    "classification-description": "Immunology, Serology and Transplantation"
                                },
                                {
                                    "classification-code": "37",
                                    "classification-description": "Drug Literature Index"
                                },
                                {
                                    "classification-code": "38",
                                    "classification-description": "Adverse Reactions Titles"
                                }
                            ]
                        },
                        {
                            "@type": "ASJC",
                            "classification": "2736"
                        },
                        {
                            "@type": "SUBJABBR",
                            "classification": "MEDI"
                        }
                    ]},
                    "tradenamegroup": {"tradenames": {
                        "trademanuitem": {"tradename": "axi cel"},
                        "@type": "TNM"
                    }},
                    "chemicalgroup": {"chemicals": {
                        "@source": "nlm",
                        "chemical": [
                            {"chemical-name": "Antigens, CD19"},
                            {"chemical-name": "axicabtagene ciloleucel"},
                            {"chemical-name": "cell-associated neurotoxicity"},
                            {"chemical-name": "Receptors, Chimeric Antigen"}
                        ]
                    }}
                },
                "grantlist": {
                    "@complete": "y",
                    "grant-text": {
                        "$": "This paper was funded by the Memorial Sloan Kettering Cancer Center Core Grant (P30 CA008748) from the National Institutes of Health/National Cancer Institute.",
                        "@xml:lang": "eng"
                    }
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2023 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "external-source": "MEDLINE",
                "dbcollection": [
                    {"$": "EMBASE"},
                    {"$": "MEDL"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "15",
                    "@timestamp": "BST 07:56:13",
                    "@year": "2023",
                    "@month": "05"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2021680219",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "640248418",
                            "@idtype": "associatedPUI"
                        },
                        {
                            "$": "946176707",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20230163750",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "36737060",
                            "@idtype": "MEDL"
                        },
                        {
                            "$": "20230478612",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20230656492",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "20239002244432",
                            "@idtype": "TPA-ID"
                        },
                        {
                            "$": "85148507055",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85148507055",
                            "@idtype": "SGR"
                        },
                        {
                            "$": "640248418",
                            "@idtype": "PUIsecondary"
                        },
                        {
                            "$": "78291899",
                            "@idtype": "OSIN"
                        }
                    ],
                    "ce:doi": "10.1080/14740338.2023.2177268"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "109",
                "reference": [
                    {
                        "ref-fulltext": "Jain T, Bar M, Kansagra AJ, et al. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American society for transplantation and cellular therapy. Biol Blood Marrow Transplant. 2019 Dec; 25 (12): 2305\u20132321.",
                        "@reference-instance-id": "OB2BibRecID-946176707-8b3f7a7c5a346c163344275d9e0f4981-1",
                        "@id": "1",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American society for transplantation and cellular therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0001",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85072519127",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "25",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "2305",
                                    "@last": "2321"
                                }
                            },
                            "ref-text": "Dec",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Jain",
                                        "ce:indexed-name": "Jain T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Bar",
                                        "ce:indexed-name": "Bar M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Kansagra",
                                        "ce:indexed-name": "Kansagra A.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Biol Blood Marrow Transplant"
                        },
                        "ce:source-text": "Jain T, Bar M, Kansagra AJ, et al. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American society for transplantation and cellular therapy. Biol Blood Marrow Transplant. 2019 Dec; 25 (12): 2305\u20132321."
                    },
                    {
                        "ref-fulltext": "Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377 (26): 2531\u20132544.",
                        "@reference-instance-id": "OB2BibRecID-946176707-e1a0504ce0deee7cc9fc8c0c7d849cf2-2",
                        "@id": "2",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0002",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85040170618",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "377",
                                    "@issue": "26"
                                },
                                "pagerange": {
                                    "@first": "2531",
                                    "@last": "2544"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Neelapu",
                                        "ce:indexed-name": "Neelapu S.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Locke",
                                        "ce:indexed-name": "Locke F.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Bartlett",
                                        "ce:indexed-name": "Bartlett N.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377 (26): 2531\u20132544."
                    },
                    {
                        "ref-fulltext": "Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380 (1): 45\u201356.",
                        "@reference-instance-id": "OB2BibRecID-946176707-c5037bb975dd66658735260dcc87e85b-3",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0003",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85058995720",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "380",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "45",
                                    "@last": "56"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Schuster",
                                        "ce:indexed-name": "Schuster S.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Bishop",
                                        "ce:indexed-name": "Bishop M.R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Tam",
                                        "ce:indexed-name": "Tam C.S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380 (1): 45\u201356."
                    },
                    {
                        "ref-fulltext": "Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396 (10254): 839\u2013852.",
                        "@reference-instance-id": "OB2BibRecID-946176707-82a789ba47d33de945d658e342a2aa23-4",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0004",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85090978508",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "396"},
                                "pagerange": {
                                    "@first": "839",
                                    "@last": "852"
                                }
                            },
                            "ref-text": "10254",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Abramson",
                                        "ce:indexed-name": "Abramson J.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Palomba",
                                        "ce:indexed-name": "Palomba M.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.I.",
                                        "@_fa": "true",
                                        "ce:surname": "Gordon",
                                        "ce:indexed-name": "Gordon L.I."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396 (10254): 839\u2013852."
                    },
                    {
                        "ref-fulltext": "Perales MA, Anderson LD Jr., Jain T, et al. Role of CD19 CAR T cells in second line large B cell lymphoma: lessons from phase 3 trials - an expert panel opinion from the American society for transplantation and cellular therapy. Transplant Cell Ther. 2022 Jun 26; 28(9): 546\u2013559.",
                        "@reference-instance-id": "OB2BibRecID-946176707-833e560caf344c01d46dd4b7985c0bc7-5",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Role of CD19 CAR T cells in second line large B cell lymphoma: lessons from phase 3 trials - an expert panel opinion from the American society for transplantation and cellular therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0005",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85135360795",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "289"},
                                "pagerange": {
                                    "@first": "546",
                                    "@last": "559"
                                }
                            },
                            "ref-text": "JrJun, 26",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Perales",
                                        "ce:indexed-name": "Perales M.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Anderson",
                                        "ce:indexed-name": "Anderson L.D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Jain",
                                        "ce:indexed-name": "Jain T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Transplant Cell Ther"
                        },
                        "ce:source-text": "Perales MA, Anderson LD Jr., Jain T, et al. Role of CD19 CAR T cells in second line large B cell lymphoma: lessons from phase 3 trials - an expert panel opinion from the American society for transplantation and cellular therapy. Transplant Cell Ther. 2022 Jun 26; 28(9): 546\u2013559."
                    },
                    {
                        "ref-fulltext": "Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022 Feb 17; 386 (7): 640\u2013654.",
                        "@reference-instance-id": "OB2BibRecID-946176707-261c1e632a5674cab68f9d5efc5f79ca-6",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0006",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85122373111",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "386",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "640",
                                    "@last": "654"
                                }
                            },
                            "ref-text": "Feb, 17",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Locke",
                                        "ce:indexed-name": "Locke F.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.B.",
                                        "@_fa": "true",
                                        "ce:surname": "Miklos",
                                        "ce:indexed-name": "Miklos D.B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Jacobson",
                                        "ce:indexed-name": "Jacobson C.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022 Feb 17; 386 (7): 640\u2013654."
                    },
                    {
                        "ref-fulltext": "Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022 Jun 18; 399 (10343): 2294\u20132308.",
                        "@reference-instance-id": "OB2BibRecID-946176707-b84e9c473cf5a3446161c377c4dceb23-7",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0007",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85132415868",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "399"},
                                "pagerange": {
                                    "@first": "2294",
                                    "@last": "2308"
                                }
                            },
                            "ref-text": "Jun, 18, 10343",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Kamdar",
                                        "ce:indexed-name": "Kamdar M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Solomon",
                                        "ce:indexed-name": "Solomon S.R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Arnason",
                                        "ce:indexed-name": "Arnason J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022 Jun 18; 399 (10343): 2294\u20132308."
                    },
                    {
                        "ref-fulltext": "Jacobson C, Locke FL, Ghobadi A, et al. Long-term (≥4 Year and ≥5 Year) overall survival (OS) by 12- and 24-Month Event-Free Survival (EFS): an Updated Analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory Large B-Cell Lymphoma (LBCL). Blood. 2021; 138: 1764.",
                        "@reference-instance-id": "OB2BibRecID-946176707-18a8ff9869308e9e47b9fe251fdb883d-8",
                        "@id": "8",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Long-term (≥4 Year and ≥5 Year) overall survival (OS) by 12- and 24-Month Event-Free Survival (EFS): an Updated Analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory Large B-Cell Lymphoma (LBCL)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0008",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85126739719",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "138"},
                                "pagerange": {"@first": "1764"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Jacobson",
                                        "ce:indexed-name": "Jacobson C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Locke",
                                        "ce:indexed-name": "Locke F.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Ghobadi",
                                        "ce:indexed-name": "Ghobadi A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Jacobson C, Locke FL, Ghobadi A, et al. Long-term (≥4 Year and ≥5 Year) overall survival (OS) by 12- and 24-Month Event-Free Survival (EFS): an Updated Analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory Large B-Cell Lymphoma (LBCL). Blood. 2021; 138: 1764."
                    },
                    {
                        "ref-fulltext": "Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019; 20 (1): 31\u201342.",
                        "@reference-instance-id": "OB2BibRecID-946176707-4620dbc51c39a435cd1a8341be50dd05-9",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0009",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85059501669",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "20",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "31",
                                    "@last": "42"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Locke",
                                        "ce:indexed-name": "Locke F.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Ghobadi",
                                        "ce:indexed-name": "Ghobadi A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Jacobson",
                                        "ce:indexed-name": "Jacobson C.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019; 20 (1): 31\u201342."
                    },
                    {
                        "ref-fulltext": "Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-Cell Lymphoma. N Engl J Med. 2021; 386 (7): 640\u2013654.",
                        "@reference-instance-id": "OB2BibRecID-946176707-1a5c7fa86eecbd5a840bcbed5a7ab829-10",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Axicabtagene ciloleucel as second-line therapy for large B-Cell Lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0010",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85122373111",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "386",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "640",
                                    "@last": "654"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Locke",
                                        "ce:indexed-name": "Locke F.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.B.",
                                        "@_fa": "true",
                                        "ce:surname": "Miklos",
                                        "ce:indexed-name": "Miklos D.B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Jacobson",
                                        "ce:indexed-name": "Jacobson C.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-Cell Lymphoma. N Engl J Med. 2021; 386 (7): 640\u2013654."
                    },
                    {
                        "ref-fulltext": "Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022; 23 (1): 91\u2013103.",
                        "@reference-instance-id": "OB2BibRecID-946176707-8f4895efe9ab5d8cf2d0a18da803c952-11",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0011",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85121575005",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "23",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "91",
                                    "@last": "103"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Jacobson",
                                        "ce:indexed-name": "Jacobson C.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Chavez",
                                        "ce:indexed-name": "Chavez J.C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Sehgal",
                                        "ce:indexed-name": "Sehgal A.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022; 23 (1): 91\u2013103."
                    },
                    {
                        "ref-fulltext": "Liu Y, Fang Y, Chen X, et al. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol. 2020 Jan 17; 5: 43.",
                        "@reference-instance-id": "OB2BibRecID-946176707-ccd99f6b691be4bee811a27c2fa5f141-12",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0012",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85077993526",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "5"},
                                "pagerange": {"@first": "43"}
                            },
                            "ref-text": "Jan, 17",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Liu",
                                        "ce:indexed-name": "Liu Y."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Fang",
                                        "ce:indexed-name": "Fang Y."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Chen",
                                        "ce:indexed-name": "Chen X."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Sci Immunol"
                        },
                        "ce:source-text": "Liu Y, Fang Y, Chen X, et al. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol. 2020 Jan 17; 5: 43."
                    },
                    {
                        "ref-fulltext": "Park JH, Riviere I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018 Feb 1; 378 (5): 449\u2013459.",
                        "@reference-instance-id": "OB2BibRecID-946176707-f4bf3b039dca6307a318d26c42ff6430-13",
                        "@id": "13",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0013",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85041377767",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "378",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "449",
                                    "@last": "459"
                                }
                            },
                            "ref-text": "Feb, 1",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Park",
                                        "ce:indexed-name": "Park J.H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Riviere",
                                        "ce:indexed-name": "Riviere I."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Gonen",
                                        "ce:indexed-name": "Gonen M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Park JH, Riviere I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018 Feb 1; 378 (5): 449\u2013459."
                    },
                    {
                        "ref-fulltext": "Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018; 24 (6): 739\u2013748.",
                        "@reference-instance-id": "OB2BibRecID-946176707-9144d206dbeccfc779bec65f3418e6df-14",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0014",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85047813147",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "24",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "739",
                                    "@last": "748"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Norelli",
                                        "ce:indexed-name": "Norelli M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Camisa",
                                        "ce:indexed-name": "Camisa B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Barbiera",
                                        "ce:indexed-name": "Barbiera G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Med"
                        },
                        "ce:source-text": "Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018; 24 (6): 739\u2013748."
                    },
                    {
                        "ref-fulltext": "Orabona C, Grohmann U, Belladonna ML, et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol. 2004 Nov; 5 (11): 1134\u20131142.",
                        "@reference-instance-id": "OB2BibRecID-946176707-371f82f4b6bfec8eef28630bbf954355-15",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2004"},
                            "ref-title": {"ref-titletext": "CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0015",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "9244231842",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "5",
                                    "@issue": "11"
                                },
                                "pagerange": {
                                    "@first": "1134",
                                    "@last": "1142"
                                }
                            },
                            "ref-text": "Nov",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Orabona",
                                        "ce:indexed-name": "Orabona C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "U.",
                                        "@_fa": "true",
                                        "ce:surname": "Grohmann",
                                        "ce:indexed-name": "Grohmann U."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Belladonna",
                                        "ce:indexed-name": "Belladonna M.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Immunol"
                        },
                        "ce:source-text": "Orabona C, Grohmann U, Belladonna ML, et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol. 2004 Nov; 5 (11): 1134\u20131142."
                    },
                    {
                        "ref-fulltext": "Giavridis T, van der Stegen SJC, Eyquem J, et al. CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018; 24 (6): 731\u2013738.",
                        "@reference-instance-id": "OB2BibRecID-946176707-946a615a75bedda3c650784be74c3ee4-16",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0016",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85047803079",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "24",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "731",
                                    "@last": "738"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Giavridis",
                                        "ce:indexed-name": "Giavridis T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.J.C.",
                                        "@_fa": "true",
                                        "ce:surname": "van der Stegen",
                                        "ce:indexed-name": "van der Stegen S.J.C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Eyquem",
                                        "ce:indexed-name": "Eyquem J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Med"
                        },
                        "ce:source-text": "Giavridis T, van der Stegen SJC, Eyquem J, et al. CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018; 24 (6): 731\u2013738."
                    },
                    {
                        "ref-fulltext": "Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016 6; Jun (6): 664\u2013679.",
                        "@reference-instance-id": "OB2BibRecID-946176707-3764fd29c24d8a92ec5c07fabfbae350-17",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0017",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85011955241",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "Jun",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "664",
                                    "@last": "679"
                                }
                            },
                            "ref-text": "6",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Teachey",
                                        "ce:indexed-name": "Teachey D.T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.F.",
                                        "@_fa": "true",
                                        "ce:surname": "Lacey",
                                        "ce:indexed-name": "Lacey S.F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Shaw",
                                        "ce:indexed-name": "Shaw P.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Discov"
                        },
                        "ce:source-text": "Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016 6; Jun (6): 664\u2013679."
                    },
                    {
                        "ref-fulltext": "Pennisi M, Jain T, Santomasso BD, et al. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020 Feb 25; 4 (4): 676\u2013686.",
                        "@reference-instance-id": "OB2BibRecID-946176707-e3915e850c6c10e5f3bc506d76c58a23-18",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0018",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85082179456",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "4",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "676",
                                    "@last": "686"
                                }
                            },
                            "ref-text": "Feb, 25",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Pennisi",
                                        "ce:indexed-name": "Pennisi M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Jain",
                                        "ce:indexed-name": "Jain T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Santomasso",
                                        "ce:indexed-name": "Santomasso B.D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Pennisi M, Jain T, Santomasso BD, et al. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020 Feb 25; 4 (4): 676\u2013686."
                    },
                    {
                        "ref-fulltext": "Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019 Apr; 25 (4): 625\u2013638.",
                        "@reference-instance-id": "OB2BibRecID-946176707-03e5e47df049e7d4f70a36af076b0a7f-19",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0019",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85062342961",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "25",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "625",
                                    "@last": "638"
                                }
                            },
                            "ref-text": "Apr",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Lee",
                                        "ce:indexed-name": "Lee D.W."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Santomasso",
                                        "ce:indexed-name": "Santomasso B.D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Locke",
                                        "ce:indexed-name": "Locke F.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Biol Blood Marrow Transplant"
                        },
                        "ce:source-text": "Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019 Apr; 25 (4): 625\u2013638."
                    },
                    {
                        "ref-fulltext": "Morris EC, Neelapu SS, Giavridis T, et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022; 22 (2): 85\u201396.",
                        "@reference-instance-id": "OB2BibRecID-946176707-2806d34eca2799a048d39a469c097b7b-20",
                        "@id": "20",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0020",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85106291891",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "22",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "85",
                                    "@last": "96"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Morris",
                                        "ce:indexed-name": "Morris E.C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Neelapu",
                                        "ce:indexed-name": "Neelapu S.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Giavridis",
                                        "ce:indexed-name": "Giavridis T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Rev Immunol"
                        },
                        "ce:source-text": "Morris EC, Neelapu SS, Giavridis T, et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022; 22 (2): 85\u201396."
                    },
                    {
                        "ref-fulltext": "Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020; 382 (14): 1331\u20131342.",
                        "@reference-instance-id": "OB2BibRecID-946176707-acf1bdb76a06f942ed58ae1b0327a6c5-21",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0021",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85082856912",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "382",
                                    "@issue": "14"
                                },
                                "pagerange": {
                                    "@first": "1331",
                                    "@last": "1342"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Munoz",
                                        "ce:indexed-name": "Munoz J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Goy",
                                        "ce:indexed-name": "Goy A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020; 382 (14): 1331\u20131342."
                    },
                    {
                        "ref-fulltext": "Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10; 124 (2): 188\u2013195.",
                        "@reference-instance-id": "OB2BibRecID-946176707-0b1cff74d49722d48761908ec4a65cad-22",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Current concepts in the diagnosis and management of cytokine release syndrome"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0022",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84904097189",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "124",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "188",
                                    "@last": "195"
                                }
                            },
                            "ref-text": "Jul, 10",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Lee",
                                        "ce:indexed-name": "Lee D.W."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Gardner",
                                        "ce:indexed-name": "Gardner R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Porter",
                                        "ce:indexed-name": "Porter D.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10; 124 (2): 188\u2013195."
                    },
                    {
                        "ref-fulltext": "Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J clin oncol. 2020; 38 (27): 3119\u20133128.",
                        "@reference-instance-id": "OB2BibRecID-946176707-203103776c81b67de43a4be696bb3ddc-23",
                        "@id": "23",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0023",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85086804860",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "38",
                                    "@issue": "27"
                                },
                                "pagerange": {
                                    "@first": "3119",
                                    "@last": "3128"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Nastoupil",
                                        "ce:indexed-name": "Nastoupil L.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Jain",
                                        "ce:indexed-name": "Jain M.D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Feng",
                                        "ce:indexed-name": "Feng L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J clin oncol"
                        },
                        "ce:source-text": "Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J clin oncol. 2020; 38 (27): 3119\u20133128."
                    },
                    {
                        "ref-fulltext": "Locke FL, Rossi JM, Neelapu SS, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020; 4 (19): 4898\u20134911.",
                        "@reference-instance-id": "OB2BibRecID-946176707-63ce91e6bca624d9e8dd7f1d29a78348-24",
                        "@id": "24",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0024",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85095741006",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "4",
                                    "@issue": "19"
                                },
                                "pagerange": {
                                    "@first": "4898",
                                    "@last": "4911"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Locke",
                                        "ce:indexed-name": "Locke F.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Rossi",
                                        "ce:indexed-name": "Rossi J.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Neelapu",
                                        "ce:indexed-name": "Neelapu S.S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Locke FL, Rossi JM, Neelapu SS, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020; 4 (19): 4898\u20134911."
                    },
                    {
                        "ref-fulltext": "Pennisi M, Sanchez-Escamilla M, Flynn JR, et al. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 2021; 5 (17): 3397\u20133406.",
                        "@reference-instance-id": "OB2BibRecID-946176707-1e60d73d513be11f2933d6276835db1b-25",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0025",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85115339187",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "5",
                                    "@issue": "17"
                                },
                                "pagerange": {
                                    "@first": "3397",
                                    "@last": "3406"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Pennisi",
                                        "ce:indexed-name": "Pennisi M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Sanchez-Escamilla",
                                        "ce:indexed-name": "Sanchez-Escamilla M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Flynn",
                                        "ce:indexed-name": "Flynn J.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Pennisi M, Sanchez-Escamilla M, Flynn JR, et al. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 2021; 5 (17): 3397\u20133406."
                    },
                    {
                        "ref-fulltext": "Orlowski RJ, Porter DL, Frey NV. The promise of chimeric antigen receptor T cells (CARTs) in leukaemia. Br J Haematol. 2017; 177 (1): 13\u201326.",
                        "@reference-instance-id": "OB2BibRecID-946176707-9b38f3bcd2076de0338027cffce16bd8-26",
                        "@id": "26",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "The promise of chimeric antigen receptor T cells (CARTs) in leukaemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0026",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85008256449",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "177",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "13",
                                    "@last": "26"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "R.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Orlowski",
                                    "ce:indexed-name": "Orlowski R.J."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "D.L.",
                                    "@_fa": "true",
                                    "ce:surname": "Porter",
                                    "ce:indexed-name": "Porter D.L."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "N.V.",
                                    "@_fa": "true",
                                    "ce:surname": "Frey",
                                    "ce:indexed-name": "Frey N.V."
                                }
                            ]},
                            "ref-sourcetitle": "Br J Haematol"
                        },
                        "ce:source-text": "Orlowski RJ, Porter DL, Frey NV. The promise of chimeric antigen receptor T cells (CARTs) in leukaemia. Br J Haematol. 2017; 177 (1): 13\u201326."
                    },
                    {
                        "ref-fulltext": "Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018 Aug; 23 (8): 943\u2013947.",
                        "@reference-instance-id": "OB2BibRecID-946176707-e533a439b279e4dd9e7d0f4dde87838f-27",
                        "@id": "27",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0027",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85045111924",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "23",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "943",
                                    "@last": "947"
                                }
                            },
                            "ref-text": "Aug",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.Q.",
                                        "@_fa": "true",
                                        "ce:surname": "Le",
                                        "ce:indexed-name": "Le R.Q."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "W.",
                                        "@_fa": "true",
                                        "ce:surname": "Yuan",
                                        "ce:indexed-name": "Yuan W."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Oncologist"
                        },
                        "ce:source-text": "Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018 Aug; 23 (8): 943\u2013947."
                    },
                    {
                        "ref-fulltext": "Strati P, Ahmed S, Furqan F, et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021; 137 (23): 3272\u20133276.",
                        "@reference-instance-id": "OB2BibRecID-946176707-633c6268ac466d255e6723277b859471-28",
                        "@id": "28",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0028",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85105369668",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "137",
                                    "@issue": "23"
                                },
                                "pagerange": {
                                    "@first": "3272",
                                    "@last": "3276"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Strati",
                                        "ce:indexed-name": "Strati P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Ahmed",
                                        "ce:indexed-name": "Ahmed S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Furqan",
                                        "ce:indexed-name": "Furqan F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Strati P, Ahmed S, Furqan F, et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021; 137 (23): 3272\u20133276."
                    },
                    {
                        "ref-fulltext": "Topp MS, van Meerten T, Houot R, et al. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021 Nov; 195 (3): 388\u2013398.",
                        "@reference-instance-id": "OB2BibRecID-946176707-f2035ab79fb50377619597f6e59238c9-29",
                        "@id": "29",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0029",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85116397779",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "195",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "388",
                                    "@last": "398"
                                }
                            },
                            "ref-text": "Nov",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Topp",
                                        "ce:indexed-name": "Topp M.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "van Meerten",
                                        "ce:indexed-name": "van Meerten T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Houot",
                                        "ce:indexed-name": "Houot R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Br J Haematol"
                        },
                        "ce:source-text": "Topp MS, van Meerten T, Houot R, et al. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021 Nov; 195 (3): 388\u2013398."
                    },
                    {
                        "ref-fulltext": "Oluwole OO, Bouabdallah K, Muñoz J, et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021; 194 (4): 690\u2013700.",
                        "@reference-instance-id": "OB2BibRecID-946176707-5e4bf8a399db98d031f57e737c7407e0-30",
                        "@id": "30",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0030",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85111010929",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "194",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "690",
                                    "@last": "700"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "O.O.",
                                        "@_fa": "true",
                                        "ce:surname": "Oluwole",
                                        "ce:indexed-name": "Oluwole O.O."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Bouabdallah",
                                        "ce:indexed-name": "Bouabdallah K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Muñoz",
                                        "ce:indexed-name": "Munoz J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Br J Haematol"
                        },
                        "ce:source-text": "Oluwole OO, Bouabdallah K, Muñoz J, et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021; 194 (4): 690\u2013700."
                    },
                    {
                        "ref-fulltext": "Huarte E, O\u2019Connor RS, Peel MT, et al. Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy. Clin Cancer Res. 2020 Dec 1; 26 (23): 6299\u20136309.",
                        "@reference-instance-id": "OB2BibRecID-946176707-6980113431a331fad7d734dd26d8b8d0-31",
                        "@id": "31",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0031",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85096716576",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "26",
                                    "@issue": "23"
                                },
                                "pagerange": {
                                    "@first": "6299",
                                    "@last": "6309"
                                }
                            },
                            "ref-text": "Dec, 1",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Huarte",
                                        "ce:indexed-name": "Huarte E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.S.",
                                        "@_fa": "true",
                                        "ce:surname": "O\u2019Connor",
                                        "ce:indexed-name": "O'Connor R.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Peel",
                                        "ce:indexed-name": "Peel M.T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Cancer Res"
                        },
                        "ce:source-text": "Huarte E, O\u2019Connor RS, Peel MT, et al. Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy. Clin Cancer Res. 2020 Dec 1; 26 (23): 6299\u20136309."
                    },
                    {
                        "ref-fulltext": "Ruella M, Kenderian SS, Shestova O, et al. Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia. 2017 Jan; 31 (1): 246\u2013248.",
                        "@reference-instance-id": "OB2BibRecID-946176707-23920eb030cdb8efcd01e22b4d625d4a-32",
                        "@id": "32",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0032",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84990878466",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "31",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "246",
                                    "@last": "248"
                                }
                            },
                            "ref-text": "Jan",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Ruella",
                                        "ce:indexed-name": "Ruella M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Kenderian",
                                        "ce:indexed-name": "Kenderian S.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "O.",
                                        "@_fa": "true",
                                        "ce:surname": "Shestova",
                                        "ce:indexed-name": "Shestova O."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Leukemia"
                        },
                        "ce:source-text": "Ruella M, Kenderian SS, Shestova O, et al. Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia. 2017 Jan; 31 (1): 246\u2013248."
                    },
                    {
                        "ref-fulltext": "Mestermann K, Giavridis T, Weber J, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci Transl Med. 2019; 11 (499): 1\u201311.",
                        "@reference-instance-id": "OB2BibRecID-946176707-2c9da471095f6a4eff8af133a0a9a6dc-33",
                        "@id": "33",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0033",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85069040779",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "11",
                                    "@issue": "499"
                                },
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "11"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Mestermann",
                                        "ce:indexed-name": "Mestermann K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Giavridis",
                                        "ce:indexed-name": "Giavridis T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Weber",
                                        "ce:indexed-name": "Weber J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Sci Transl Med"
                        },
                        "ce:source-text": "Mestermann K, Giavridis T, Weber J, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci Transl Med. 2019; 11 (499): 1\u201311."
                    },
                    {
                        "ref-fulltext": "Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019 Feb 14; 133 (7): 697\u2013709.",
                        "@reference-instance-id": "OB2BibRecID-946176707-a363c2a459a73b587c0d103e274ab859-34",
                        "@id": "34",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0034",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85058641028",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "133",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "697",
                                    "@last": "709"
                                }
                            },
                            "ref-text": "Feb, 14",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Sterner",
                                        "ce:indexed-name": "Sterner R.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Sakemura",
                                        "ce:indexed-name": "Sakemura R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Cox",
                                        "ce:indexed-name": "Cox M.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019 Feb 14; 133 (7): 697\u2013709."
                    },
                    {
                        "ref-fulltext": "Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan; 15 (1): 47\u201362.",
                        "@reference-instance-id": "OB2BibRecID-946176707-8c90e4420bca6959508fae3344c84648-35",
                        "@id": "35",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Chimeric antigen receptor T-cell therapy - assessment and management of toxicities"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0035",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85038265543",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "15",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "47",
                                    "@last": "62"
                                }
                            },
                            "ref-text": "Jan",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Neelapu",
                                        "ce:indexed-name": "Neelapu S.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Tummala",
                                        "ce:indexed-name": "Tummala S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Kebriaei",
                                        "ce:indexed-name": "Kebriaei P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Rev Clin Oncol"
                        },
                        "ce:source-text": "Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan; 15 (1): 47\u201362."
                    },
                    {
                        "ref-fulltext": "Hoogland AI, Barata A, Logue J, et al. Change in neurocognitive performance among patients with non-Hodgkin lymphoma in the first year after chimeric antigen receptor T cell therapy. Transplantat Cell Ther. 2022; 28 (6): 305.e1\u2013305.e9.",
                        "@reference-instance-id": "OB2BibRecID-946176707-6786537f1aeee1dd8ab314b6adac9cf3-36",
                        "@id": "36",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Change in neurocognitive performance among patients with non-Hodgkin lymphoma in the first year after chimeric antigen receptor T cell therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0036",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "e9",
                                    "@idtype": "ARTNUM"
                                },
                                {
                                    "$": "85129920846",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "28",
                                    "@issue": "6"
                                },
                                "pagerange": {"@first": "305"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.I.",
                                        "@_fa": "true",
                                        "ce:surname": "Hoogland",
                                        "ce:indexed-name": "Hoogland A.I."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Barata",
                                        "ce:indexed-name": "Barata A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Logue",
                                        "ce:indexed-name": "Logue J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Transplantat Cell Ther"
                        },
                        "ce:source-text": "Hoogland AI, Barata A, Logue J, et al. Change in neurocognitive performance among patients with non-Hodgkin lymphoma in the first year after chimeric antigen receptor T cell therapy. Transplantat Cell Ther. 2022; 28 (6): 305.e1\u2013305.e9."
                    },
                    {
                        "ref-fulltext": "Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018 8; Aug (8): 958\u2013971.",
                        "@reference-instance-id": "OB2BibRecID-946176707-e35b0ad9abd79f98704f68a8f34d9712-37",
                        "@id": "37",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0037",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85052999490",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "Aug",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "958",
                                    "@last": "971"
                                }
                            },
                            "ref-text": "8",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Santomasso",
                                        "ce:indexed-name": "Santomasso B.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Park",
                                        "ce:indexed-name": "Park J.H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Salloum",
                                        "ce:indexed-name": "Salloum D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Discov"
                        },
                        "ce:source-text": "Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018 8; Aug (8): 958\u2013971."
                    },
                    {
                        "ref-fulltext": "Gust J, Hay KA, Hanafi LA, et al. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov. 2017 Dec; 7 (12): 1404\u20131419.",
                        "@reference-instance-id": "OB2BibRecID-946176707-a19254c913c2b9731b7e131160a340f9-38",
                        "@id": "38",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0038",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85037359093",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "7",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "1404",
                                    "@last": "1419"
                                }
                            },
                            "ref-text": "Dec",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Gust",
                                        "ce:indexed-name": "Gust J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hay",
                                        "ce:indexed-name": "Hay K.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hanafi",
                                        "ce:indexed-name": "Hanafi L.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Discov"
                        },
                        "ce:source-text": "Gust J, Hay KA, Hanafi LA, et al. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov. 2017 Dec; 7 (12): 1404\u20131419."
                    },
                    {
                        "ref-fulltext": "Gust J, Finney OC, Li D, et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann Neurol. 2019 Jul; 86 (1): 42\u201354.",
                        "@reference-instance-id": "OB2BibRecID-946176707-265720efd0f72f82faa11788abf24647-39",
                        "@id": "39",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0039",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85067257350",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "86",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "42",
                                    "@last": "54"
                                }
                            },
                            "ref-text": "Jul",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Gust",
                                        "ce:indexed-name": "Gust J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "O.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Finney",
                                        "ce:indexed-name": "Finney O.C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Neurol"
                        },
                        "ce:source-text": "Gust J, Finney OC, Li D, et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann Neurol. 2019 Jul; 86 (1): 42\u201354."
                    },
                    {
                        "ref-fulltext": "Sofroniew MV. Multiple roles for astrocytes as effectors of cytokines and inflammatory mediators. Neuroscientist. 2014 Apr; 20 (2): 160\u2013172.",
                        "@reference-instance-id": "OB2BibRecID-946176707-f0f365e8e4f6d16fab6b537c240c63a0-40",
                        "@id": "40",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Multiple roles for astrocytes as effectors of cytokines and inflammatory mediators"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0040",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84895733280",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "20",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "160",
                                    "@last": "172"
                                }
                            },
                            "ref-text": "Apr",
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "M.V.",
                                "@_fa": "true",
                                "ce:surname": "Sofroniew",
                                "ce:indexed-name": "Sofroniew M.V."
                            }]},
                            "ref-sourcetitle": "Neuroscientist"
                        },
                        "ce:source-text": "Sofroniew MV. Multiple roles for astrocytes as effectors of cytokines and inflammatory mediators. Neuroscientist. 2014 Apr; 20 (2): 160\u2013172."
                    },
                    {
                        "ref-fulltext": "Gutierrez EG, Banks WA, Kastin AJ. Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier. J Neuroimmunol. 1994 Dec; 55 (2): 153\u2013160.",
                        "@reference-instance-id": "OB2BibRecID-946176707-15f73bab49c900d93705762106e83197-41",
                        "@id": "41",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "1994"},
                            "ref-title": {"ref-titletext": "Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0041",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "0028556463",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "55",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "153",
                                    "@last": "160"
                                }
                            },
                            "ref-text": "Dec",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "E.G.",
                                    "@_fa": "true",
                                    "ce:surname": "Gutierrez",
                                    "ce:indexed-name": "Gutierrez E.G."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "W.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Banks",
                                    "ce:indexed-name": "Banks W.A."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "A.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Kastin",
                                    "ce:indexed-name": "Kastin A.J."
                                }
                            ]},
                            "ref-sourcetitle": "J Neuroimmunol"
                        },
                        "ce:source-text": "Gutierrez EG, Banks WA, Kastin AJ. Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier. J Neuroimmunol. 1994 Dec; 55 (2): 153\u2013160."
                    },
                    {
                        "ref-fulltext": "Parker KR, Migliorini D, Perkey E, et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell. 2020 Oct 1; 183 (1): 126\u2013142.e17.",
                        "@reference-instance-id": "OB2BibRecID-946176707-8e2405fae1626e06da35fea5e1b7317f-42",
                        "@id": "42",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0042",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "e17",
                                    "@idtype": "ARTNUM"
                                },
                                {
                                    "$": "85091675643",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "183",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "126",
                                    "@last": "142"
                                }
                            },
                            "ref-text": "Oct, 1",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Parker",
                                        "ce:indexed-name": "Parker K.R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Migliorini",
                                        "ce:indexed-name": "Migliorini D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Perkey",
                                        "ce:indexed-name": "Perkey E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cell"
                        },
                        "ce:source-text": "Parker KR, Migliorini D, Perkey E, et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell. 2020 Oct 1; 183 (1): 126\u2013142.e17."
                    },
                    {
                        "ref-fulltext": "Johnsrud A, Craig J, Baird J, et al. Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. Blood Adv. 2021; 5 (21): 4465\u20134475.",
                        "@reference-instance-id": "OB2BibRecID-946176707-925a1cc367098880460f1fc338f49148-43",
                        "@id": "43",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0043",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85118868412",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "5",
                                    "@issue": "21"
                                },
                                "pagerange": {
                                    "@first": "4465",
                                    "@last": "4475"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Johnsrud",
                                        "ce:indexed-name": "Johnsrud A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Craig",
                                        "ce:indexed-name": "Craig J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Baird",
                                        "ce:indexed-name": "Baird J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Johnsrud A, Craig J, Baird J, et al. Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. Blood Adv. 2021; 5 (21): 4465\u20134475."
                    },
                    {
                        "ref-fulltext": "Maus MV, Alexander S, Bishop MR, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020 Dec; 8 (2): 1\u201325.",
                        "@reference-instance-id": "OB2BibRecID-946176707-38779a31317fdc21f2b3306316703a8e-44",
                        "@id": "44",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0044",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85097932204",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "8",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "25"
                                }
                            },
                            "ref-text": "Dec",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Maus",
                                        "ce:indexed-name": "Maus M.V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Alexander",
                                        "ce:indexed-name": "Alexander S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Bishop",
                                        "ce:indexed-name": "Bishop M.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Immunother Cancer"
                        },
                        "ce:source-text": "Maus MV, Alexander S, Bishop MR, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020 Dec; 8 (2): 1\u201325."
                    },
                    {
                        "ref-fulltext": "Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti\u2013IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008; 112 (10): 3959\u20133964.",
                        "@reference-instance-id": "OB2BibRecID-946176707-f46079e1d92aff1b8e75d78e45edbd1c-45",
                        "@id": "45",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2008"},
                            "ref-title": {"ref-titletext": "Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti\u2013IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0045",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "58149154996",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "112",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "3959",
                                    "@last": "3964"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Nishimoto",
                                        "ce:indexed-name": "Nishimoto N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Terao",
                                        "ce:indexed-name": "Terao K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Mima",
                                        "ce:indexed-name": "Mima T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti\u2013IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008; 112 (10): 3959\u20133964."
                    },
                    {
                        "ref-fulltext": "Locke FL, Neelapu SS, Bartlett NL, et al. Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for patients with refractory, aggressive Non-Hodgkin Lymphoma (NHL). Blood. 2017; 130 (Supplement 1): 1547\u20131547.",
                        "@reference-instance-id": "OB2BibRecID-946176707-5d54987804001dabac34f23187a7b922-46",
                        "@id": "46",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for patients with refractory, aggressive Non-Hodgkin Lymphoma (NHL)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0046",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85053004799",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "130"},
                                "pagerange": {"@first": "1547"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Locke",
                                        "ce:indexed-name": "Locke F.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Neelapu",
                                        "ce:indexed-name": "Neelapu S.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Bartlett",
                                        "ce:indexed-name": "Bartlett N.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Locke FL, Neelapu SS, Bartlett NL, et al. Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for patients with refractory, aggressive Non-Hodgkin Lymphoma (NHL). Blood. 2017; 130 (Supplement 1): 1547\u20131547."
                    },
                    {
                        "ref-fulltext": "Park JH, Sauter CS, Palomba ML, et al. A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma. Blood. 2021; 138 (Supplement 1): 96\u201396.",
                        "@reference-instance-id": "OB2BibRecID-946176707-cd066b12d2203028b28d75ee559be309-47",
                        "@id": "47",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0047",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85127313385",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "138"},
                                "pagerange": {"@first": "96"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Park",
                                        "ce:indexed-name": "Park J.H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Sauter",
                                        "ce:indexed-name": "Sauter C.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Palomba",
                                        "ce:indexed-name": "Palomba M.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Park JH, Sauter CS, Palomba ML, et al. A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma. Blood. 2021; 138 (Supplement 1): 96\u201396."
                    },
                    {
                        "ref-fulltext": "Jordan MB, Allen CE, Greenberg J, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019 Nov; 66 (11): e27929.",
                        "@reference-instance-id": "OB2BibRecID-946176707-454d8e921c66821fc7478e863d054309-48",
                        "@id": "48",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0048",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85069692640",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "66",
                                    "@issue": "11"
                                },
                                "pagerange": {"@first": "e27929"}
                            },
                            "ref-text": "Nov",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.B.",
                                        "@_fa": "true",
                                        "ce:surname": "Jordan",
                                        "ce:indexed-name": "Jordan M.B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Allen",
                                        "ce:indexed-name": "Allen C.E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Greenberg",
                                        "ce:indexed-name": "Greenberg J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Pediatr Blood Cancer"
                        },
                        "ce:source-text": "Jordan MB, Allen CE, Greenberg J, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019 Nov; 66 (11): e27929."
                    },
                    {
                        "ref-fulltext": "Lichtenstein DA, Schischlik F, Shao L, et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood. 2021 Dec 16; 138 (24): 2469\u20132484.",
                        "@reference-instance-id": "OB2BibRecID-946176707-aa2272fc4e30de3721b356a37228401d-49",
                        "@id": "49",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0049",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85119658059",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "138",
                                    "@issue": "24"
                                },
                                "pagerange": {
                                    "@first": "2469",
                                    "@last": "2484"
                                }
                            },
                            "ref-text": "Dec, 16",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Lichtenstein",
                                        "ce:indexed-name": "Lichtenstein D.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Schischlik",
                                        "ce:indexed-name": "Schischlik F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Shao",
                                        "ce:indexed-name": "Shao L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Lichtenstein DA, Schischlik F, Shao L, et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood. 2021 Dec 16; 138 (24): 2469\u20132484."
                    },
                    {
                        "ref-fulltext": "Masih KE, Ligon JA, Yates B, et al. Consequences of hemophagocytic lymphohistiocytosis-like cytokine release syndrome toxicities and concurrent bacteremia. Pediatr Blood Cancer. 2021 Oct; 68 (10): e29247.",
                        "@reference-instance-id": "OB2BibRecID-946176707-4e59c61cf68afdff8b75ab65e874ecad-50",
                        "@id": "50",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Consequences of hemophagocytic lymphohistiocytosis-like cytokine release syndrome toxicities and concurrent bacteremia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0050",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85111376513",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "68",
                                    "@issue": "10"
                                },
                                "pagerange": {"@first": "e29247"}
                            },
                            "ref-text": "Oct",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Masih",
                                        "ce:indexed-name": "Masih K.E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Ligon",
                                        "ce:indexed-name": "Ligon J.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Yates",
                                        "ce:indexed-name": "Yates B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Pediatr Blood Cancer"
                        },
                        "ce:source-text": "Masih KE, Ligon JA, Yates B, et al. Consequences of hemophagocytic lymphohistiocytosis-like cytokine release syndrome toxicities and concurrent bacteremia. Pediatr Blood Cancer. 2021 Oct; 68 (10): e29247."
                    },
                    {
                        "ref-fulltext": "Shah NN, Highfill SL, Shalabi H, et al. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. J clin oncol. 2020; 38 (17): 1938\u20131950.",
                        "@reference-instance-id": "OB2BibRecID-946176707-783a1bafcb0ca4f3c7d8bc45049161dd-51",
                        "@id": "51",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: updated Results From a Phase I Anti-CD22 CAR T-Cell Trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0051",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85084220891",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "38",
                                    "@issue": "17"
                                },
                                "pagerange": {
                                    "@first": "1938",
                                    "@last": "1950"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.N.",
                                        "@_fa": "true",
                                        "ce:surname": "Shah",
                                        "ce:indexed-name": "Shah N.N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Highfill",
                                        "ce:indexed-name": "Highfill S.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Shalabi",
                                        "ce:indexed-name": "Shalabi H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J clin oncol"
                        },
                        "ce:source-text": "Shah NN, Highfill SL, Shalabi H, et al. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. J clin oncol. 2020; 38 (17): 1938\u20131950."
                    },
                    {
                        "ref-fulltext": "Ahmed S, Furqan F, Strati P, et al. Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel). J clin oncol. 2020; 38 (15_suppl): 8057\u20138057.",
                        "@reference-instance-id": "OB2BibRecID-946176707-78128f96d4d127bd87d174ac92f6d9e0-52",
                        "@id": "52",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0052",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85141416628",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "38"},
                                "pagerange": {"@first": "8057"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Ahmed",
                                        "ce:indexed-name": "Ahmed S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Furqan",
                                        "ce:indexed-name": "Furqan F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Strati",
                                        "ce:indexed-name": "Strati P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J clin oncol"
                        },
                        "ce:source-text": "Ahmed S, Furqan F, Strati P, et al. Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel). J clin oncol. 2020; 38 (15_suppl): 8057\u20138057."
                    },
                    {
                        "ref-fulltext": "Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 2019 Dec; 6 (12): e630\u2013e637.",
                        "@reference-instance-id": "OB2BibRecID-946176707-b4c96264f0e0dcde82e5df46ed0c0ea0-53",
                        "@id": "53",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0053",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85075336167",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "6",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "e630",
                                    "@last": "e637"
                                }
                            },
                            "ref-text": "Dec",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Ahmed",
                                        "ce:indexed-name": "Ahmed A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Merrill",
                                        "ce:indexed-name": "Merrill S.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Alsawah",
                                        "ce:indexed-name": "Alsawah F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Haematol"
                        },
                        "ce:source-text": "Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 2019 Dec; 6 (12): e630\u2013e637."
                    },
                    {
                        "ref-fulltext": "Bailey SR, Vatsa S, Larson RC, et al. Blockade or deletion of IFNγ reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies. Blood Cancer Discovery. 2022; 3 (2): 136\u2013153.",
                        "@reference-instance-id": "OB2BibRecID-946176707-7bba1a85e478a720f2228e1521dd0d28-54",
                        "@id": "54",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Blockade or deletion of IFNγ reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0054",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85127973739",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "3",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "136",
                                    "@last": "153"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Bailey",
                                        "ce:indexed-name": "Bailey S.R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Vatsa",
                                        "ce:indexed-name": "Vatsa S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Larson",
                                        "ce:indexed-name": "Larson R.C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Cancer Discovery"
                        },
                        "ce:source-text": "Bailey SR, Vatsa S, Larson RC, et al. Blockade or deletion of IFNγ reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies. Blood Cancer Discovery. 2022; 3 (2): 136\u2013153."
                    },
                    {
                        "ref-fulltext": "Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016 Jun 30; 127 (26): 3321\u20133330.",
                        "@reference-instance-id": "OB2BibRecID-946176707-fc5cb1ac66e9863d6e0af0795bfeb44c-55",
                        "@id": "55",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Toxicities of chimeric antigen receptor T cells: recognition and management"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0055",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84977477922",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "127",
                                    "@issue": "26"
                                },
                                "pagerange": {
                                    "@first": "3321",
                                    "@last": "3330"
                                }
                            },
                            "ref-text": "Jun, 30",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "J.N.",
                                    "@_fa": "true",
                                    "ce:surname": "Brudno",
                                    "ce:indexed-name": "Brudno J.N."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.N.",
                                    "@_fa": "true",
                                    "ce:surname": "Kochenderfer",
                                    "ce:indexed-name": "Kochenderfer J.N."
                                }
                            ]},
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016 Jun 30; 127 (26): 3321\u20133330."
                    },
                    {
                        "ref-fulltext": "Neelapu SS, Jacobson CA, Oluwole OO, et al. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020 Jun 4; 135 (23): 2106\u20132109.",
                        "@reference-instance-id": "OB2BibRecID-946176707-cbb33d3a91a3fca5a2bb7688d4339f1b-56",
                        "@id": "56",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0056",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85085664138",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "135",
                                    "@issue": "23"
                                },
                                "pagerange": {
                                    "@first": "2106",
                                    "@last": "2109"
                                }
                            },
                            "ref-text": "Jun, 4",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Neelapu",
                                        "ce:indexed-name": "Neelapu S.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Jacobson",
                                        "ce:indexed-name": "Jacobson C.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "O.O.",
                                        "@_fa": "true",
                                        "ce:surname": "Oluwole",
                                        "ce:indexed-name": "Oluwole O.O."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Neelapu SS, Jacobson CA, Oluwole OO, et al. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020 Jun 4; 135 (23): 2106\u20132109."
                    },
                    {
                        "ref-fulltext": "Meng J, Wu X, Sun Z, et al. Efficacy and safety of CAR-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel for the treatment of hematologic malignancies: a systematic review and meta-analysis. Front Oncol. 2021; 11: 698607.",
                        "@reference-instance-id": "OB2BibRecID-946176707-6cacf42f92d10b8024ded55805d62571-57",
                        "@id": "57",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Efficacy and safety of CAR-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel for the treatment of hematologic malignancies: a systematic review and meta-analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0057",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85112349853",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "11"},
                                "pagerange": {"@first": "698607"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Meng",
                                        "ce:indexed-name": "Meng J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Wu",
                                        "ce:indexed-name": "Wu X."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Z.",
                                        "@_fa": "true",
                                        "ce:surname": "Sun",
                                        "ce:indexed-name": "Sun Z."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Front Oncol"
                        },
                        "ce:source-text": "Meng J, Wu X, Sun Z, et al. Efficacy and safety of CAR-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel for the treatment of hematologic malignancies: a systematic review and meta-analysis. Front Oncol. 2021; 11: 698607."
                    },
                    {
                        "ref-fulltext": "Oluwole OO, Jansen JP, Lin VW, et al. Comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed/refractory large B cell lymphoma. Biol Blood Marrow Transplant. 2020 Sep; 26 (9): 1581\u20131588.",
                        "@reference-instance-id": "OB2BibRecID-946176707-fba2f0e79997998e3f2cd9af255c2b76-58",
                        "@id": "58",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed/refractory large B cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0058",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85088116766",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "26",
                                    "@issue": "9"
                                },
                                "pagerange": {
                                    "@first": "1581",
                                    "@last": "1588"
                                }
                            },
                            "ref-text": "Sep",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "O.O.",
                                        "@_fa": "true",
                                        "ce:surname": "Oluwole",
                                        "ce:indexed-name": "Oluwole O.O."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.P.",
                                        "@_fa": "true",
                                        "ce:surname": "Jansen",
                                        "ce:indexed-name": "Jansen J.P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "V.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Lin",
                                        "ce:indexed-name": "Lin V.W."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Biol Blood Marrow Transplant"
                        },
                        "ce:source-text": "Oluwole OO, Jansen JP, Lin VW, et al. Comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed/refractory large B cell lymphoma. Biol Blood Marrow Transplant. 2020 Sep; 26 (9): 1581\u20131588."
                    },
                    {
                        "ref-fulltext": "Gauthier J, Gazeau N, Hirayama AV, et al. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. Blood. 2022 Jun 30; 139 (26): 3722\u20133731.",
                        "@reference-instance-id": "OB2BibRecID-946176707-a535cf642971bc38efa67f6027e5375c-59",
                        "@id": "59",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0059",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85133153646",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "139",
                                    "@issue": "26"
                                },
                                "pagerange": {
                                    "@first": "3722",
                                    "@last": "3731"
                                }
                            },
                            "ref-text": "Jun, 30",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Gauthier",
                                        "ce:indexed-name": "Gauthier J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Gazeau",
                                        "ce:indexed-name": "Gazeau N."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Hirayama",
                                        "ce:indexed-name": "Hirayama A.V."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Gauthier J, Gazeau N, Hirayama AV, et al. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. Blood. 2022 Jun 30; 139 (26): 3722\u20133731."
                    },
                    {
                        "ref-fulltext": "Wudhikarn K, Pennisi M, Garcia-Recio M, et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv. 2020 Jul 14; 4 (13): 3024\u20133033.",
                        "@reference-instance-id": "OB2BibRecID-946176707-5e9346cd0e8afdb9ddbd468a35252f5e-60",
                        "@id": "60",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0060",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85088255538",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "4",
                                    "@issue": "13"
                                },
                                "pagerange": {
                                    "@first": "3024",
                                    "@last": "3033"
                                }
                            },
                            "ref-text": "Jul, 14",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Wudhikarn",
                                        "ce:indexed-name": "Wudhikarn K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Pennisi",
                                        "ce:indexed-name": "Pennisi M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Garcia-Recio",
                                        "ce:indexed-name": "Garcia-Recio M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Wudhikarn K, Pennisi M, Garcia-Recio M, et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv. 2020 Jul 14; 4 (13): 3024\u20133033."
                    },
                    {
                        "ref-fulltext": "Alvi RM, Frigault MJ, Fradley MG, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol. 2019 Dec 24; 74 (25): 3099\u20133108.",
                        "@reference-instance-id": "OB2BibRecID-946176707-b9aba3b972935c767ff807e6a8186809-61",
                        "@id": "61",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0061",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85076026538",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "74",
                                    "@issue": "25"
                                },
                                "pagerange": {
                                    "@first": "3099",
                                    "@last": "3108"
                                }
                            },
                            "ref-text": "Dec, 24",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Alvi",
                                        "ce:indexed-name": "Alvi R.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Frigault",
                                        "ce:indexed-name": "Frigault M.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.G.",
                                        "@_fa": "true",
                                        "ce:surname": "Fradley",
                                        "ce:indexed-name": "Fradley M.G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Am Coll Cardiol"
                        },
                        "ce:source-text": "Alvi RM, Frigault MJ, Fradley MG, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol. 2019 Dec 24; 74 (25): 3099\u20133108."
                    },
                    {
                        "ref-fulltext": "Lefebvre B, Kang Y, Smith AM, et al. Cardiovascular Effects of CAR T Cell Therapy: a Retrospective Study. JACC CardioOncol. 2020 Jun; 2 (2): 193\u2013203.",
                        "@reference-instance-id": "OB2BibRecID-946176707-a183774e9ae36b80e8eaf94a255e9901-62",
                        "@id": "62",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Cardiovascular Effects of CAR T Cell Therapy: a Retrospective Study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0062",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85094924176",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "2",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "193",
                                    "@last": "203"
                                }
                            },
                            "ref-text": "Jun",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Lefebvre",
                                        "ce:indexed-name": "Lefebvre B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Kang",
                                        "ce:indexed-name": "Kang Y."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Smith",
                                        "ce:indexed-name": "Smith A.M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JACC CardioOncol"
                        },
                        "ce:source-text": "Lefebvre B, Kang Y, Smith AM, et al. Cardiovascular Effects of CAR T Cell Therapy: a Retrospective Study. JACC CardioOncol. 2020 Jun; 2 (2): 193\u2013203."
                    },
                    {
                        "ref-fulltext": "Shalabi H, Sachdev V, Kulshreshtha A, et al. Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies. J Immunother Cancer. 2020 Sep; 8 (2): 1\u20139.",
                        "@reference-instance-id": "OB2BibRecID-946176707-d9b9d0b7bb6456c3d925372590bdc7f8-63",
                        "@id": "63",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0063",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85090320241",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "8",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "9"
                                }
                            },
                            "ref-text": "Sep",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Shalabi",
                                        "ce:indexed-name": "Shalabi H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Sachdev",
                                        "ce:indexed-name": "Sachdev V."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Kulshreshtha",
                                        "ce:indexed-name": "Kulshreshtha A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Immunother Cancer"
                        },
                        "ce:source-text": "Shalabi H, Sachdev V, Kulshreshtha A, et al. Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies. J Immunother Cancer. 2020 Sep; 8 (2): 1\u20139."
                    },
                    {
                        "ref-fulltext": "Ganatra S, Redd R, Hayek SS, et al. Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma. Circulation. 2020 Oct 27; 142 (17): 1687\u20131690.",
                        "@reference-instance-id": "OB2BibRecID-946176707-79c4bdc267a42b1c544ed1a9d665c371-64",
                        "@id": "64",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0064",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85094866581",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "142",
                                    "@issue": "17"
                                },
                                "pagerange": {
                                    "@first": "1687",
                                    "@last": "1690"
                                }
                            },
                            "ref-text": "Oct, 27",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Ganatra",
                                        "ce:indexed-name": "Ganatra S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Redd",
                                        "ce:indexed-name": "Redd R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Hayek",
                                        "ce:indexed-name": "Hayek S.S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Circulation"
                        },
                        "ce:source-text": "Ganatra S, Redd R, Hayek SS, et al. Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma. Circulation. 2020 Oct 27; 142 (17): 1687\u20131690."
                    },
                    {
                        "ref-fulltext": "Burstein DS, Maude S, Grupp S, et al. Cardiac profile of chimeric antigen receptor t cell therapy in children: a single-institution experience. Biol Blood Marrow Transplant. 2018 Aug; 24 (8): 1590\u20131595.",
                        "@reference-instance-id": "OB2BibRecID-946176707-2fe84eae8f3fa42561db48aba3dbfedb-65",
                        "@id": "65",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Cardiac profile of chimeric antigen receptor t cell therapy in children: a single-institution experience"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0065",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85048544437",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "24",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "1590",
                                    "@last": "1595"
                                }
                            },
                            "ref-text": "Aug",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Burstein",
                                        "ce:indexed-name": "Burstein D.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Maude",
                                        "ce:indexed-name": "Maude S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Grupp",
                                        "ce:indexed-name": "Grupp S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Biol Blood Marrow Transplant"
                        },
                        "ce:source-text": "Burstein DS, Maude S, Grupp S, et al. Cardiac profile of chimeric antigen receptor t cell therapy in children: a single-institution experience. Biol Blood Marrow Transplant. 2018 Aug; 24 (8): 1590\u20131595."
                    },
                    {
                        "ref-fulltext": "Goldman A, Maor E, Bomze D, et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J Am Coll Cardiol. 2021 Nov 2; 78 (18): 1800\u20131813.",
                        "@reference-instance-id": "OB2BibRecID-946176707-fcff8f3715c37ec1088117487833dd66-66",
                        "@id": "66",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0066",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85117202191",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "78",
                                    "@issue": "18"
                                },
                                "pagerange": {
                                    "@first": "1800",
                                    "@last": "1813"
                                }
                            },
                            "ref-text": "Nov, 2",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Goldman",
                                        "ce:indexed-name": "Goldman A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Maor",
                                        "ce:indexed-name": "Maor E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Bomze",
                                        "ce:indexed-name": "Bomze D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Am Coll Cardiol"
                        },
                        "ce:source-text": "Goldman A, Maor E, Bomze D, et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J Am Coll Cardiol. 2021 Nov 2; 78 (18): 1800\u20131813."
                    },
                    {
                        "ref-fulltext": "Ghosh AK, Chen DH, Guha A, et al. CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity? JACC CardioOncol. 2020 Mar; 2 (1): 97\u2013109.",
                        "@reference-instance-id": "OB2BibRecID-946176707-1d1b5d107202a59e0015dd4a8b3f0194-67",
                        "@id": "67",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity?"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0067",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85084383017",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "2",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "97",
                                    "@last": "109"
                                }
                            },
                            "ref-text": "Mar",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Ghosh",
                                        "ce:indexed-name": "Ghosh A.K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Chen",
                                        "ce:indexed-name": "Chen D.H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Guha",
                                        "ce:indexed-name": "Guha A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JACC CardioOncol"
                        },
                        "ce:source-text": "Ghosh AK, Chen DH, Guha A, et al. CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity? JACC CardioOncol. 2020 Mar; 2 (1): 97\u2013109."
                    },
                    {
                        "ref-fulltext": "Bondeelle L, Di Blasi R, Samy L, et al. CAR T cells-associated delayed lung toxicity\u2013a case series. Eur Respir J. 2020; 56 (suppl 64): 746.",
                        "@reference-instance-id": "OB2BibRecID-946176707-54f7a4ac403faeec485e1f75c5a9bef5-68",
                        "@id": "68",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "CAR T cells-associated delayed lung toxicity\u2013a case series"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0068",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85159548944",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "56"},
                                "pagerange": {"@first": "746"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Bondeelle",
                                        "ce:indexed-name": "Bondeelle L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Di Blasi",
                                        "ce:indexed-name": "Di Blasi R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Samy",
                                        "ce:indexed-name": "Samy L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Eur Respir J"
                        },
                        "ce:source-text": "Bondeelle L, Di Blasi R, Samy L, et al. CAR T cells-associated delayed lung toxicity\u2013a case series. Eur Respir J. 2020; 56 (suppl 64): 746."
                    },
                    {
                        "ref-fulltext": "Sun Z, Xie C, Liu H, et al. CD19 CAR-T cell therapy induced immunotherapy associated interstitial pneumonitis: a case report. Front Immunol. 2022; 13: 778192.",
                        "@reference-instance-id": "OB2BibRecID-946176707-d3d621d7240d70e8c3252384310b2d61-69",
                        "@id": "69",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "CD19 CAR-T cell therapy induced immunotherapy associated interstitial pneumonitis: a case report"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0069",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85124558936",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "13"},
                                "pagerange": {"@first": "778192"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Z.",
                                        "@_fa": "true",
                                        "ce:surname": "Sun",
                                        "ce:indexed-name": "Sun Z."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Xie",
                                        "ce:indexed-name": "Xie C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Liu",
                                        "ce:indexed-name": "Liu H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Front Immunol"
                        },
                        "ce:source-text": "Sun Z, Xie C, Liu H, et al. CD19 CAR-T cell therapy induced immunotherapy associated interstitial pneumonitis: a case report. Front Immunol. 2022; 13: 778192."
                    },
                    {
                        "ref-fulltext": "Gupta S, Seethapathy H, Strohbehn IA, et al. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma. Am J Kidney Dis. 2020 Jul; 76 (1): 63\u201371.",
                        "@reference-instance-id": "OB2BibRecID-946176707-bc6b121e55b9dbf5aa7a10c4f7ec700c-70",
                        "@id": "70",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0070",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85078635798",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "76",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "63",
                                    "@last": "71"
                                }
                            },
                            "ref-text": "Jul",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Gupta",
                                        "ce:indexed-name": "Gupta S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Seethapathy",
                                        "ce:indexed-name": "Seethapathy H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "I.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Strohbehn",
                                        "ce:indexed-name": "Strohbehn I.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Am J Kidney Dis"
                        },
                        "ce:source-text": "Gupta S, Seethapathy H, Strohbehn IA, et al. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma. Am J Kidney Dis. 2020 Jul; 76 (1): 63\u201371."
                    },
                    {
                        "ref-fulltext": "Gutgarts V, Jain T, Zheng J, et al. Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery. Biol Blood Marrow Transplant. 2020; 26 (6): 1071\u20131076.",
                        "@reference-instance-id": "OB2BibRecID-946176707-e9e2bd84df6463a857a7a44fcbd23800-71",
                        "@id": "71",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0071",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85082798786",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "26",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "1071",
                                    "@last": "1076"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Gutgarts",
                                        "ce:indexed-name": "Gutgarts V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Jain",
                                        "ce:indexed-name": "Jain T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Zheng",
                                        "ce:indexed-name": "Zheng J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Biol Blood Marrow Transplant"
                        },
                        "ce:source-text": "Gutgarts V, Jain T, Zheng J, et al. Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery. Biol Blood Marrow Transplant. 2020; 26 (6): 1071\u20131076."
                    },
                    {
                        "ref-fulltext": "Myers RM, Fitzgerald J, Elgarten CW, et al. Acute kidney injury after chimeric antigen receptor T-cell therapy for pediatric acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2019; 25 (3 Supplement): S168\u2013S169.",
                        "@reference-instance-id": "OB2BibRecID-946176707-686c134517e6f1f88eb985105e1801c0-72",
                        "@id": "72",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Acute kidney injury after chimeric antigen receptor T-cell therapy for pediatric acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0072",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85068675146",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "25"},
                                "pagerange": {
                                    "@first": "S168",
                                    "@last": "S169"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Myers",
                                        "ce:indexed-name": "Myers R.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Fitzgerald",
                                        "ce:indexed-name": "Fitzgerald J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Elgarten",
                                        "ce:indexed-name": "Elgarten C.W."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Biol Blood Marrow Transplant"
                        },
                        "ce:source-text": "Myers RM, Fitzgerald J, Elgarten CW, et al. Acute kidney injury after chimeric antigen receptor T-cell therapy for pediatric acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2019; 25 (3 Supplement): S168\u2013S169."
                    },
                    {
                        "ref-fulltext": "Farooqui N, Jpt S-G, Miao J, et al. Incidence and risk factors for acute kidney injury after chimeric antigen receptor T-cell therapy. Mayo Clin Proc. 2022 Jul; 97 (7): 1294\u20131304.",
                        "@reference-instance-id": "OB2BibRecID-946176707-02b133a72fe50f326a8a47fa173fc691-73",
                        "@id": "73",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Incidence and risk factors for acute kidney injury after chimeric antigen receptor T-cell therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0073",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85133254315",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "97",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "1294",
                                    "@last": "1304"
                                }
                            },
                            "ref-text": "Jul",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Farooqui",
                                        "ce:indexed-name": "Farooqui N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.-G.",
                                        "@_fa": "true",
                                        "ce:surname": "Jpt",
                                        "ce:indexed-name": "Jpt S.-G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Miao",
                                        "ce:indexed-name": "Miao J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Mayo Clin Proc"
                        },
                        "ce:source-text": "Farooqui N, Jpt S-G, Miao J, et al. Incidence and risk factors for acute kidney injury after chimeric antigen receptor T-cell therapy. Mayo Clin Proc. 2022 Jul; 97 (7): 1294\u20131304."
                    },
                    {
                        "ref-fulltext": "Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018 Feb 1; 378 (5): 439\u2013448.",
                        "@reference-instance-id": "OB2BibRecID-946176707-320b9c2a74bc1641b2f3882a00a80bf2-74",
                        "@id": "74",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0074",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85041428116",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "378",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "439",
                                    "@last": "448"
                                }
                            },
                            "ref-text": "Feb, 1",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Maude",
                                        "ce:indexed-name": "Maude S.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Laetsch",
                                        "ce:indexed-name": "Laetsch T.W."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Buechner",
                                        "ce:indexed-name": "Buechner J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018 Feb 1; 378 (5): 439\u2013448."
                    },
                    {
                        "ref-fulltext": "Abu-Sbeih H, Tang T, Ali FS, et al. Gastrointestinal adverse events observed after chimeric antigen receptor T-cell therapy. Am J Clin Oncol. 2019 Oct; 42 (10): 789\u2013796.",
                        "@reference-instance-id": "OB2BibRecID-946176707-d35c48e038d057fb3011e955ca6c27d1-75",
                        "@id": "75",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Gastrointestinal adverse events observed after chimeric antigen receptor T-cell therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0075",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85072020775",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "42",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "789",
                                    "@last": "796"
                                }
                            },
                            "ref-text": "Oct",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Abu-Sbeih",
                                        "ce:indexed-name": "Abu-Sbeih H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Tang",
                                        "ce:indexed-name": "Tang T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Ali",
                                        "ce:indexed-name": "Ali F.S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Am J Clin Oncol"
                        },
                        "ce:source-text": "Abu-Sbeih H, Tang T, Ali FS, et al. Gastrointestinal adverse events observed after chimeric antigen receptor T-cell therapy. Am J Clin Oncol. 2019 Oct; 42 (10): 789\u2013796."
                    },
                    {
                        "ref-fulltext": "Sandler RD, Tattersall RS, Schoemans H, et al. Diagnosis and management of secondary HLH/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Front Immunol. 2020; 11: 524.",
                        "@reference-instance-id": "OB2BibRecID-946176707-57e73a7046fc73819ded0077373e3e18-76",
                        "@id": "76",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Diagnosis and management of secondary HLH/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0076",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85083477448",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "11"},
                                "pagerange": {"@first": "524"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Sandler",
                                        "ce:indexed-name": "Sandler R.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Tattersall",
                                        "ce:indexed-name": "Tattersall R.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Schoemans",
                                        "ce:indexed-name": "Schoemans H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Front Immunol"
                        },
                        "ce:source-text": "Sandler RD, Tattersall RS, Schoemans H, et al. Diagnosis and management of secondary HLH/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Front Immunol. 2020; 11: 524."
                    },
                    {
                        "ref-fulltext": "Wang Y, Liu Y, Tan X, et al. Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection. Leukemia. 2020 Oct; 34 (10): 2704\u20132707.",
                        "@reference-instance-id": "OB2BibRecID-946176707-bf8bc8f3f23219bfd178f5e739653233-77",
                        "@id": "77",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0077",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85086864770",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "34",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "2704",
                                    "@last": "2707"
                                }
                            },
                            "ref-text": "Oct",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang Y."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Liu",
                                        "ce:indexed-name": "Liu Y."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Tan",
                                        "ce:indexed-name": "Tan X."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Leukemia"
                        },
                        "ce:source-text": "Wang Y, Liu Y, Tan X, et al. Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection. Leukemia. 2020 Oct; 34 (10): 2704\u20132707."
                    },
                    {
                        "ref-fulltext": "Han L, Zhou J, Zhou K, et al. Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus. J Immunother Cancer. 2020 Aug; 8 (2): 1\u201310.",
                        "@reference-instance-id": "OB2BibRecID-946176707-022deb489ad2137ff027c682ee893abc-78",
                        "@id": "78",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0078",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85089540213",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "8",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "10"
                                }
                            },
                            "ref-text": "Aug",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Han",
                                        "ce:indexed-name": "Han L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhou",
                                        "ce:indexed-name": "Zhou J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhou",
                                        "ce:indexed-name": "Zhou K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Immunother Cancer"
                        },
                        "ce:source-text": "Han L, Zhou J, Zhou K, et al. Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus. J Immunother Cancer. 2020 Aug; 8 (2): 1\u201310."
                    },
                    {
                        "ref-fulltext": "Liu W, Lv R, Huang W, et al. The risk of hepatitis B reactivation is controllable in patients with concomitant hepatitis B virus infection during chimeric antigen receptor T-cell therapy. Blood. 2019; 134 (Supplement_1): 2913\u20132913.",
                        "@reference-instance-id": "OB2BibRecID-946176707-e6c3c17322c47a40d0a72cdca3554e49-79",
                        "@id": "79",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "The risk of hepatitis B reactivation is controllable in patients with concomitant hepatitis B virus infection during chimeric antigen receptor T-cell therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0079",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85089082604",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "134"},
                                "pagerange": {"@first": "2913"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "W.",
                                        "@_fa": "true",
                                        "ce:surname": "Liu",
                                        "ce:indexed-name": "Liu W."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Lv",
                                        "ce:indexed-name": "Lv R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "W.",
                                        "@_fa": "true",
                                        "ce:surname": "Huang",
                                        "ce:indexed-name": "Huang W."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Liu W, Lv R, Huang W, et al. The risk of hepatitis B reactivation is controllable in patients with concomitant hepatitis B virus infection during chimeric antigen receptor T-cell therapy. Blood. 2019; 134 (Supplement_1): 2913\u20132913."
                    },
                    {
                        "ref-fulltext": "Wei J, Zhu X, Mao X, et al. Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma. J Immunother Cancer. 2019 Nov 21; 7 (1): 315.",
                        "@reference-instance-id": "OB2BibRecID-946176707-8f01f6808738df770a3a498ae06c7d04-80",
                        "@id": "80",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0080",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85075475691",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "7",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "315"}
                            },
                            "ref-text": "Nov, 21",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Wei",
                                        "ce:indexed-name": "Wei J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhu",
                                        "ce:indexed-name": "Zhu X."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Mao",
                                        "ce:indexed-name": "Mao X."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Immunother Cancer"
                        },
                        "ce:source-text": "Wei J, Zhu X, Mao X, et al. Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma. J Immunother Cancer. 2019 Nov 21; 7 (1): 315."
                    },
                    {
                        "ref-fulltext": "Kenzik KM, Johnson PC, Bhatia R, et al. Assessment of Hospitalizations and Emergency Department Visits After Chimeric Antigen Receptor T-Cell Therapy Among Commercially Insured Patients. JAMA Oncol. 2022; 8(7): 1068\u20131070.",
                        "@reference-instance-id": "OB2BibRecID-946176707-c4c26e86c959157ca3bb0a5fcc43d8e2-81",
                        "@id": "81",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Assessment of Hospitalizations and Emergency Department Visits After Chimeric Antigen Receptor T-Cell Therapy Among Commercially Insured Patients"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0081",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85129847733",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "87"},
                                "pagerange": {
                                    "@first": "1068",
                                    "@last": "1070"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Kenzik",
                                        "ce:indexed-name": "Kenzik K.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Johnson",
                                        "ce:indexed-name": "Johnson P.C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Bhatia",
                                        "ce:indexed-name": "Bhatia R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JAMA Oncol"
                        },
                        "ce:source-text": "Kenzik KM, Johnson PC, Bhatia R, et al. Assessment of Hospitalizations and Emergency Department Visits After Chimeric Antigen Receptor T-Cell Therapy Among Commercially Insured Patients. JAMA Oncol. 2022; 8(7): 1068\u20131070."
                    },
                    {
                        "ref-fulltext": "Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018 Jan 4; 131 (1): 121\u2013130.",
                        "@reference-instance-id": "OB2BibRecID-946176707-71cf05df3ef12d33af875ce4888077bd-82",
                        "@id": "82",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0082",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85040089946",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "131",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "121",
                                    "@last": "130"
                                }
                            },
                            "ref-text": "Jan, 4",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hill",
                                        "ce:indexed-name": "Hill J.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hay",
                                        "ce:indexed-name": "Hay K.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018 Jan 4; 131 (1): 121\u2013130."
                    },
                    {
                        "ref-fulltext": "Baird JH, Epstein DJ, Tamaresis JS, et al. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Adv. 2021 Jan 12; 5 (1): 143\u2013155.",
                        "@reference-instance-id": "OB2BibRecID-946176707-b3ab38b798e8dfcc65b7cb53fa7f5865-83",
                        "@id": "83",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0083",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85099191851",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "5",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "143",
                                    "@last": "155"
                                }
                            },
                            "ref-text": "Jan, 12",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Baird",
                                        "ce:indexed-name": "Baird J.H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Epstein",
                                        "ce:indexed-name": "Epstein D.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Tamaresis",
                                        "ce:indexed-name": "Tamaresis J.S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Baird JH, Epstein DJ, Tamaresis JS, et al. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Adv. 2021 Jan 12; 5 (1): 143\u2013155."
                    },
                    {
                        "ref-fulltext": "Logue JM, Zucchetti E, Bachmeier CA, et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021 Apr 1; 106 (4): 978\u2013986.",
                        "@reference-instance-id": "OB2BibRecID-946176707-8547e2fb7e8476cb85608cd277b09b95-84",
                        "@id": "84",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0084",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85103683194",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "106",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "978",
                                    "@last": "986"
                                }
                            },
                            "ref-text": "Apr, 1",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Logue",
                                        "ce:indexed-name": "Logue J.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Zucchetti",
                                        "ce:indexed-name": "Zucchetti E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Bachmeier",
                                        "ce:indexed-name": "Bachmeier C.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Haematologica"
                        },
                        "ce:source-text": "Logue JM, Zucchetti E, Bachmeier CA, et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021 Apr 1; 106 (4): 978\u2013986."
                    },
                    {
                        "ref-fulltext": "Wudhikarn K, Palomba ML, Pennisi M, et al. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J. 2020 Aug 5; 10 (8): 79.",
                        "@reference-instance-id": "OB2BibRecID-946176707-7d20c7c0fe91696dfeb8f34675e2fa8a-85",
                        "@id": "85",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0085",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85089023617",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "10",
                                    "@issue": "8"
                                },
                                "pagerange": {"@first": "79"}
                            },
                            "ref-text": "Aug, 5",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Wudhikarn",
                                        "ce:indexed-name": "Wudhikarn K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Palomba",
                                        "ce:indexed-name": "Palomba M.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Pennisi",
                                        "ce:indexed-name": "Pennisi M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Cancer J"
                        },
                        "ce:source-text": "Wudhikarn K, Palomba ML, Pennisi M, et al. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J. 2020 Aug 5; 10 (8): 79."
                    },
                    {
                        "ref-fulltext": "Strati P, Varma A, Adkins S, et al. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica. 2021 Oct 1; 106 (10): 2667\u20132672.",
                        "@reference-instance-id": "OB2BibRecID-946176707-4dcee25c5353cbecc3fe253d25121c1e-86",
                        "@id": "86",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0086",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85105265129",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "106",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "2667",
                                    "@last": "2672"
                                }
                            },
                            "ref-text": "Oct, 1",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Strati",
                                        "ce:indexed-name": "Strati P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Varma",
                                        "ce:indexed-name": "Varma A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Adkins",
                                        "ce:indexed-name": "Adkins S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Haematologica"
                        },
                        "ce:source-text": "Strati P, Varma A, Adkins S, et al. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica. 2021 Oct 1; 106 (10): 2667\u20132672."
                    },
                    {
                        "ref-fulltext": "Bishop MR, Dickinson M, Purtill D, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022 Feb 17; 386 (7): 629\u2013639.",
                        "@reference-instance-id": "OB2BibRecID-946176707-5f17f457928f594bda672251a144ae90-87",
                        "@id": "87",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0087",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85122390017",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "386",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "629",
                                    "@last": "639"
                                }
                            },
                            "ref-text": "Feb, 17",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Bishop",
                                        "ce:indexed-name": "Bishop M.R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Dickinson",
                                        "ce:indexed-name": "Dickinson M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Purtill",
                                        "ce:indexed-name": "Purtill D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Bishop MR, Dickinson M, Purtill D, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022 Feb 17; 386 (7): 629\u2013639."
                    },
                    {
                        "ref-fulltext": "Meir J, Abid MA, Abid MB. State of the CAR-T: risk of infections with chimeric antigen receptor T-Cell therapy and determinants of SARS-CoV-2 vaccine responses. Transplant Cell Ther. 2021 Dec; 27 (12): 973\u2013987.",
                        "@reference-instance-id": "OB2BibRecID-946176707-27ff30e172fbb39e5690fccf641c5069-88",
                        "@id": "88",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "State of the CAR-T: risk of infections with chimeric antigen receptor T-Cell therapy and determinants of SARS-CoV-2 vaccine responses"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0088",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85118698451",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "27",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "973",
                                    "@last": "987"
                                }
                            },
                            "ref-text": "Dec",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Meir",
                                    "ce:indexed-name": "Meir J."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "M.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Abid",
                                    "ce:indexed-name": "Abid M.A."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "M.B.",
                                    "@_fa": "true",
                                    "ce:surname": "Abid",
                                    "ce:indexed-name": "Abid M.B."
                                }
                            ]},
                            "ref-sourcetitle": "Transplant Cell Ther"
                        },
                        "ce:source-text": "Meir J, Abid MA, Abid MB. State of the CAR-T: risk of infections with chimeric antigen receptor T-Cell therapy and determinants of SARS-CoV-2 vaccine responses. Transplant Cell Ther. 2021 Dec; 27 (12): 973\u2013987."
                    },
                    {
                        "ref-fulltext": "Cordeiro A, Bezerra ED, Hirayama AV, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant. 2020 Jan; 26 (1): 26\u201333.",
                        "@reference-instance-id": "OB2BibRecID-946176707-6af6d169e731cadf54d9a4e9c27af69f-89",
                        "@id": "89",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0089",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85072258712",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "26",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "26",
                                    "@last": "33"
                                }
                            },
                            "ref-text": "Jan",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Cordeiro",
                                        "ce:indexed-name": "Cordeiro A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Bezerra",
                                        "ce:indexed-name": "Bezerra E.D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Hirayama",
                                        "ce:indexed-name": "Hirayama A.V."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Biol Blood Marrow Transplant"
                        },
                        "ce:source-text": "Cordeiro A, Bezerra ED, Hirayama AV, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant. 2020 Jan; 26 (1): 26\u201333."
                    },
                    {
                        "ref-fulltext": "Spanjaart AM, Ljungman P, de La Camara R, et al. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Leukemia. 2021 Dec; 35 (12): 3585\u20133588.",
                        "@reference-instance-id": "OB2BibRecID-946176707-97da51f25f4e3a859067d099ff327175-90",
                        "@id": "90",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0090",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85118627482",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "35",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "3585",
                                    "@last": "3588"
                                }
                            },
                            "ref-text": "Dec",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Spanjaart",
                                        "ce:indexed-name": "Spanjaart A.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Ljungman",
                                        "ce:indexed-name": "Ljungman P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "de La Camara",
                                        "ce:indexed-name": "de La Camara R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Leukemia"
                        },
                        "ce:source-text": "Spanjaart AM, Ljungman P, de La Camara R, et al. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Leukemia. 2021 Dec; 35 (12): 3585\u20133588."
                    },
                    {
                        "ref-fulltext": "Hensley MK, Bain WG, Jacobs J, et al. Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: a Case Study. Clin Infect Dis. 2021 Aug 2; 73 (3): e815\u2013e821.",
                        "@reference-instance-id": "OB2BibRecID-946176707-37d5aea7f39d8185d9dd7bd1cfcf49bc-91",
                        "@id": "91",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: a Case Study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0091",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85113712510",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "73",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "e815",
                                    "@last": "e821"
                                }
                            },
                            "ref-text": "Aug, 2",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Hensley",
                                        "ce:indexed-name": "Hensley M.K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "W.G.",
                                        "@_fa": "true",
                                        "ce:surname": "Bain",
                                        "ce:indexed-name": "Bain W.G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Jacobs",
                                        "ce:indexed-name": "Jacobs J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Infect Dis"
                        },
                        "ce:source-text": "Hensley MK, Bain WG, Jacobs J, et al. Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: a Case Study. Clin Infect Dis. 2021 Aug 2; 73 (3): e815\u2013e821."
                    },
                    {
                        "ref-fulltext": "Maurer K, Saucier A, Kim HT, et al. COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Adv. 2021 Feb 9; 5 (3): 861\u2013871.",
                        "@reference-instance-id": "OB2BibRecID-946176707-df01ca57dbe31fab39ab95e60d38877e-92",
                        "@id": "92",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0092",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85101844981",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "5",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "861",
                                    "@last": "871"
                                }
                            },
                            "ref-text": "Feb, 9",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Maurer",
                                        "ce:indexed-name": "Maurer K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Saucier",
                                        "ce:indexed-name": "Saucier A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim H.T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Maurer K, Saucier A, Kim HT, et al. COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Adv. 2021 Feb 9; 5 (3): 861\u2013871."
                    },
                    {
                        "ref-fulltext": "Haidar G, Dorritie K, Farah R, et al. Invasive mold infections after chimeric antigen receptor-modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis. Clin Infect Dis. 2020 Jul 27; 71 (3): 672\u2013676.",
                        "@reference-instance-id": "OB2BibRecID-946176707-0d01d8ee0ac93dce477a6f21e9a4483c-93",
                        "@id": "93",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Invasive mold infections after chimeric antigen receptor-modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0093",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85088846749",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "71",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "672",
                                    "@last": "676"
                                }
                            },
                            "ref-text": "Jul, 27",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Haidar",
                                        "ce:indexed-name": "Haidar G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Dorritie",
                                        "ce:indexed-name": "Dorritie K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Farah",
                                        "ce:indexed-name": "Farah R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Infect Dis"
                        },
                        "ce:source-text": "Haidar G, Dorritie K, Farah R, et al. Invasive mold infections after chimeric antigen receptor-modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis. Clin Infect Dis. 2020 Jul 27; 71 (3): 672\u2013676."
                    },
                    {
                        "ref-fulltext": "Garner W, Samanta P, Haidar G. Invasive fungal infections after anti-CD19 chimeric antigen receptor-modified t-cell therapy: state of the evidence and future directions. J Fungi (Basel). 2021 Feb 23; 7 (2): 1\u201313.",
                        "@reference-instance-id": "OB2BibRecID-946176707-3a79feba41f5dc8cfe86cb77f742f48d-94",
                        "@id": "94",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Invasive fungal infections after anti-CD19 chimeric antigen receptor-modified t-cell therapy: state of the evidence and future directions"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0094",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85102344806",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "7",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "13"
                                }
                            },
                            "ref-text": "Feb, 23",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "W.",
                                    "@_fa": "true",
                                    "ce:surname": "Garner",
                                    "ce:indexed-name": "Garner W."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "P.",
                                    "@_fa": "true",
                                    "ce:surname": "Samanta",
                                    "ce:indexed-name": "Samanta P."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "G.",
                                    "@_fa": "true",
                                    "ce:surname": "Haidar",
                                    "ce:indexed-name": "Haidar G."
                                }
                            ]},
                            "ref-sourcetitle": "J Fungi (Basel)"
                        },
                        "ce:source-text": "Garner W, Samanta P, Haidar G. Invasive fungal infections after anti-CD19 chimeric antigen receptor-modified t-cell therapy: state of the evidence and future directions. J Fungi (Basel). 2021 Feb 23; 7 (2): 1\u201313."
                    },
                    {
                        "ref-fulltext": "Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020 Aug 20; 136 (8): 925\u2013935.",
                        "@reference-instance-id": "OB2BibRecID-946176707-54a250036414fe5d80b548098c127fd1-95",
                        "@id": "95",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0095",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85089786737",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "136",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "925",
                                    "@last": "935"
                                }
                            },
                            "ref-text": "Aug, 20",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "J.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Hill",
                                    "ce:indexed-name": "Hill J.A."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "S.K.",
                                    "@_fa": "true",
                                    "ce:surname": "Seo",
                                    "ce:indexed-name": "Seo S.K."
                                }
                            ]},
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020 Aug 20; 136 (8): 925\u2013935."
                    },
                    {
                        "ref-fulltext": "Ibrahim Y-A, Christian C, Peter B, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020; 105 (2): 297\u2013316.",
                        "@reference-instance-id": "OB2BibRecID-946176707-5590bde922e002ea1f08115263415498-96",
                        "@id": "96",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0096",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85078868386",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "105",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "297",
                                    "@last": "316"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.-A.",
                                        "@_fa": "true",
                                        "ce:surname": "Ibrahim",
                                        "ce:indexed-name": "Ibrahim Y.-A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Christian",
                                        "ce:indexed-name": "Christian C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Peter",
                                        "ce:indexed-name": "Peter B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Haematologica"
                        },
                        "ce:source-text": "Ibrahim Y-A, Christian C, Peter B, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020; 105 (2): 297\u2013316."
                    },
                    {
                        "ref-fulltext": "Hayden PJ, Roddie C, Bader P, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022 Mar; 33 (3): 259\u2013275.",
                        "@reference-instance-id": "OB2BibRecID-946176707-4feacb78f732088a889d52be1073f046-97",
                        "@id": "97",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0097",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85123279981",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "33",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "259",
                                    "@last": "275"
                                }
                            },
                            "ref-text": "Mar",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Hayden",
                                        "ce:indexed-name": "Hayden P.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Roddie",
                                        "ce:indexed-name": "Roddie C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Bader",
                                        "ce:indexed-name": "Bader P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Hayden PJ, Roddie C, Bader P, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022 Mar; 33 (3): 259\u2013275."
                    },
                    {
                        "ref-fulltext": "Barmettler S, Ong MS, Farmer JR, et al. Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Network Open. 2018 Nov 2; 1 (7): e184169.",
                        "@reference-instance-id": "OB2BibRecID-946176707-e096c467e2bedea31f4f92a82033414e-98",
                        "@id": "98",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0098",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85067196740",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "1",
                                    "@issue": "7"
                                },
                                "pagerange": {"@first": "e184169"}
                            },
                            "ref-text": "Nov, 2",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Barmettler",
                                        "ce:indexed-name": "Barmettler S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Ong",
                                        "ce:indexed-name": "Ong M.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Farmer",
                                        "ce:indexed-name": "Farmer J.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JAMA Network Open"
                        },
                        "ce:source-text": "Barmettler S, Ong MS, Farmer JR, et al. Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Network Open. 2018 Nov 2; 1 (7): e184169."
                    },
                    {
                        "ref-fulltext": "Hill JA, Krantz EM, Hay KA, et al. Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. Blood Adv. 2019 Nov 26; 3 (22): 3590\u20133601.",
                        "@reference-instance-id": "OB2BibRecID-946176707-58634789e99b1804cf7f36cf136eef41-99",
                        "@id": "99",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0099",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85074643408",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "3",
                                    "@issue": "22"
                                },
                                "pagerange": {
                                    "@first": "3590",
                                    "@last": "3601"
                                }
                            },
                            "ref-text": "Nov, 26",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hill",
                                        "ce:indexed-name": "Hill J.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Krantz",
                                        "ce:indexed-name": "Krantz E.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hay",
                                        "ce:indexed-name": "Hay K.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Hill JA, Krantz EM, Hay KA, et al. Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. Blood Adv. 2019 Nov 26; 3 (22): 3590\u20133601."
                    },
                    {
                        "ref-fulltext": "Hill JA, Giralt S, Torgerson TR, et al. CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Rev. 2019; 38: 100596.",
                        "@reference-instance-id": "OB2BibRecID-946176707-babe5478cbf28377a00da3d4e4538222-100",
                        "@id": "100",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0100",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85070404978",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "38"},
                                "pagerange": {"@first": "100596"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hill",
                                        "ce:indexed-name": "Hill J.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Giralt",
                                        "ce:indexed-name": "Giralt S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Torgerson",
                                        "ce:indexed-name": "Torgerson T.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Rev"
                        },
                        "ce:source-text": "Hill JA, Giralt S, Torgerson TR, et al. CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Rev. 2019; 38: 100596."
                    },
                    {
                        "ref-fulltext": "Kampouri E, Walti CS, Gauthier J, et al. Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. Expert Rev Hematol. 2022; 11: 1\u201316.",
                        "@reference-instance-id": "OB2BibRecID-946176707-84f93dfa93eb22f3880e3a448319cbcb-101",
                        "@id": "101",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0101",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85159548198",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "11"},
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "16"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Kampouri",
                                        "ce:indexed-name": "Kampouri E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Walti",
                                        "ce:indexed-name": "Walti C.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Gauthier",
                                        "ce:indexed-name": "Gauthier J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Expert Rev Hematol"
                        },
                        "ce:source-text": "Kampouri E, Walti CS, Gauthier J, et al. Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. Expert Rev Hematol. 2022; 11: 1\u201316."
                    },
                    {
                        "ref-fulltext": "Los-Arcos I, Iacoboni G, Aguilar-Guisado M, et al. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection. 2021 Apr; 49 (2): 215\u2013231.",
                        "@reference-instance-id": "OB2BibRecID-946176707-e1b756d10ee2e93d58580ea48a492843-102",
                        "@id": "102",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0102",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85091490289",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "49",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "215",
                                    "@last": "231"
                                }
                            },
                            "ref-text": "Apr",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Los-Arcos",
                                        "ce:indexed-name": "Los-Arcos I."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Iacoboni",
                                        "ce:indexed-name": "Iacoboni G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Aguilar-Guisado",
                                        "ce:indexed-name": "Aguilar-Guisado M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Infection"
                        },
                        "ce:source-text": "Los-Arcos I, Iacoboni G, Aguilar-Guisado M, et al. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection. 2021 Apr; 49 (2): 215\u2013231."
                    },
                    {
                        "ref-fulltext": "Nahas GR, Komanduri KV, Pereira D, et al. Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk Lymphoma. 2020 Apr; 61 (4): 940\u2013943.",
                        "@reference-instance-id": "OB2BibRecID-946176707-1eea78594dca003dc414c74630deebc1-103",
                        "@id": "103",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0103",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85076116345",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "61",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "940",
                                    "@last": "943"
                                }
                            },
                            "ref-text": "Apr",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Nahas",
                                        "ce:indexed-name": "Nahas G.R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Komanduri",
                                        "ce:indexed-name": "Komanduri K.V."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Pereira",
                                        "ce:indexed-name": "Pereira D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Leuk Lymphoma"
                        },
                        "ce:source-text": "Nahas GR, Komanduri KV, Pereira D, et al. Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk Lymphoma. 2020 Apr; 61 (4): 940\u2013943."
                    },
                    {
                        "ref-fulltext": "Jain T, Knezevic A, Pennisi M, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020 Aug 11; 4 (15): 3776\u20133787.",
                        "@reference-instance-id": "OB2BibRecID-946176707-d87a5659b0a6c446c0a1949e083fc2f9-104",
                        "@id": "104",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0104",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85090556703",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "4",
                                    "@issue": "15"
                                },
                                "pagerange": {
                                    "@first": "3776",
                                    "@last": "3787"
                                }
                            },
                            "ref-text": "Aug, 11",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Jain",
                                        "ce:indexed-name": "Jain T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Knezevic",
                                        "ce:indexed-name": "Knezevic A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Pennisi",
                                        "ce:indexed-name": "Pennisi M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Jain T, Knezevic A, Pennisi M, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020 Aug 11; 4 (15): 3776\u20133787."
                    },
                    {
                        "ref-fulltext": "Rejeski K, Perez A, Sesques P, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021 Dec 16; 138 (24): 2499\u20132513.",
                        "@reference-instance-id": "OB2BibRecID-946176707-85bfd8d52537830fb240192d7e1be447-105",
                        "@id": "105",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0105",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85118697349",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "138",
                                    "@issue": "24"
                                },
                                "pagerange": {
                                    "@first": "2499",
                                    "@last": "2513"
                                }
                            },
                            "ref-text": "Dec, 16",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Rejeski",
                                        "ce:indexed-name": "Rejeski K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Perez",
                                        "ce:indexed-name": "Perez A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Sesques",
                                        "ce:indexed-name": "Sesques P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Rejeski K, Perez A, Sesques P, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021 Dec 16; 138 (24): 2499\u20132513."
                    },
                    {
                        "ref-fulltext": "Juluri KR, Wu QV, Voutsinas J, et al. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv. 2022 Apr 12; 6 (7): 2055\u20132068.",
                        "@reference-instance-id": "OB2BibRecID-946176707-a57614ade19758ad0cf15b4b1c1c570a-106",
                        "@id": "106",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0106",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85126539614",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "6",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "2055",
                                    "@last": "2068"
                                }
                            },
                            "ref-text": "Apr, 12",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Juluri",
                                        "ce:indexed-name": "Juluri K.R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Q.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Wu",
                                        "ce:indexed-name": "Wu Q.V."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Voutsinas",
                                        "ce:indexed-name": "Voutsinas J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Juluri KR, Wu QV, Voutsinas J, et al. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv. 2022 Apr 12; 6 (7): 2055\u20132068."
                    },
                    {
                        "ref-fulltext": "Galli E, Allain V, Di Blasi R, et al. G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma. Bone Marrow Transplant. 2020 Dec; 55 (12): 2347\u20132349.",
                        "@reference-instance-id": "OB2BibRecID-946176707-aedc779b2119c2e2768e61e213febee8-107",
                        "@id": "107",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0107",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85088633789",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "55",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "2347",
                                    "@last": "2349"
                                }
                            },
                            "ref-text": "Dec",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Galli",
                                        "ce:indexed-name": "Galli E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Allain",
                                        "ce:indexed-name": "Allain V."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Di Blasi",
                                        "ce:indexed-name": "Di Blasi R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Bone Marrow Transplant"
                        },
                        "ce:source-text": "Galli E, Allain V, Di Blasi R, et al. G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma. Bone Marrow Transplant. 2020 Dec; 55 (12): 2347\u20132349."
                    },
                    {
                        "ref-fulltext": "Hashmi H, Shockley A, Davis JA. \u2018Save the day with a stem cell rescue\u2019: use of autologous hematopoietic stem cell boost for hematopoietic recovery after CAR T cell therapy. Bone Marrow Transplant. 2022 Mar; 57 (3): 504\u2013506.",
                        "@reference-instance-id": "OB2BibRecID-946176707-a272266835d7f164997f8772444ef296-108",
                        "@id": "108",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "\u2018Save the day with a stem cell rescue\u2019: use of autologous hematopoietic stem cell boost for hematopoietic recovery after CAR T cell therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0108",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85122831483",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "57",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "504",
                                    "@last": "506"
                                }
                            },
                            "ref-text": "Mar",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "H.",
                                    "@_fa": "true",
                                    "ce:surname": "Hashmi",
                                    "ce:indexed-name": "Hashmi H."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Shockley",
                                    "ce:indexed-name": "Shockley A."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "J.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Davis",
                                    "ce:indexed-name": "Davis J.A."
                                }
                            ]},
                            "ref-sourcetitle": "Bone Marrow Transplant"
                        },
                        "ce:source-text": "Hashmi H, Shockley A, Davis JA. \u2018Save the day with a stem cell rescue\u2019: use of autologous hematopoietic stem cell boost for hematopoietic recovery after CAR T cell therapy. Bone Marrow Transplant. 2022 Mar; 57 (3): 504\u2013506."
                    },
                    {
                        "ref-fulltext": "Smith M, Dai A, Ghilardi G, et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med. 2022 Apr; 28 (4): 713\u2013723.",
                        "@reference-instance-id": "OB2BibRecID-946176707-285e8d5234ecc86ca4a262c085cedfea-109",
                        "@id": "109",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0109",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85126185139",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "28",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "713",
                                    "@last": "723"
                                }
                            },
                            "ref-text": "Apr",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Smith",
                                        "ce:indexed-name": "Smith M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Dai",
                                        "ce:indexed-name": "Dai A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Ghilardi",
                                        "ce:indexed-name": "Ghilardi G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Med"
                        },
                        "ce:source-text": "Smith M, Dai A, Ghilardi G, et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med. 2022 Apr; 28 (4): 713\u2013723."
                    }
                ]
            }}
        }
    },
    "affiliation": [
        {
            "affiliation-city": "New York",
            "@id": "60009343",
            "affilname": "Memorial Sloan-Kettering Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Madrid",
            "@id": "60033237",
            "affilname": "Hospital General Universitario Gregorio Marañón",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60033237",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "New York",
            "@id": "60007997",
            "affilname": "Weill Cornell Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "coredata": {
        "srctype": "j",
        "eid": "2-s2.0-85148507055",
        "dc:description": "Introduction: CD19-directed chimeric antigen receptor (CAR) T-cell therapy is a highly effective therapy for patients with relapsed/refractory large B-cell lymphoma (LBCL) and three CD19 CAR T-cell products (axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel) are currently approved for this indication. Despite the clinical benefit of CD19 directed CAR T-cell therapy, this treatment is associated with significant morbidity from treatment-emergent toxicities. Areas covered: This Review discusses the safety considerations of axicabtagene ciloleucel in patients with LBCL. This includes discussion of the frequently observed immune-mediated toxicities of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Additionally, we review CAR T-cell therapy related cytopenias, infection, organ dysfunction and the more recently described hemophagocytic lymphohistiocytosis. Expert Opinion: A thorough understanding of the toxicities associated with CD19-directed CAR T-cell therapy will facilitate the optimal selection of patients for this therapy. Furthermore, knowledge of preventative measures of CAR T-cell related complications, and early recognition and appropriate intervention will lead to the safe administration of these therapies, and ultimately improved outcomes for our patients.",
        "pubmed-id": "36737060",
        "prism:coverDate": "2023-01-01",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85148507055",
        "dc:creator": {"author": [{
            "ce:given-name": "Karthik",
            "preferred-name": {
                "ce:given-name": "Karthik",
                "ce:initials": "K.",
                "ce:surname": "Nath",
                "ce:indexed-name": "Nath K."
            },
            "@seq": "1",
            "ce:initials": "K.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60009343",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
            },
            "ce:surname": "Nath",
            "@auid": "57211201733",
            "author-url": "https://api.elsevier.com/content/author/author_id/57211201733",
            "ce:indexed-name": "Nath K."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85148507055"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85148507055&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85148507055&origin=inward"
            }
        ],
        "source-id": "21349",
        "citedby-count": "1",
        "prism:volume": "22",
        "subtype": "ar",
        "dc:title": "Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma",
        "openaccess": "0",
        "prism:issn": "1744764X 14740338",
        "publishercopyright": "© 2023 Informa UK Limited, trading as Taylor & Francis Group.",
        "prism:issueIdentifier": "1",
        "subtypeDescription": "Article",
        "prism:publicationName": "Expert Opinion on Drug Safety",
        "prism:pageRange": "5-15",
        "prism:endingPage": "15",
        "openaccessFlag": "false",
        "prism:doi": "10.1080/14740338.2023.2177268",
        "prism:startingPage": "5",
        "dc:identifier": "SCOPUS_ID:85148507055",
        "dc:publisher": "Taylor and Francis Ltd."
    },
    "idxterms": {"mainterm": [
        {
            "$": "Antigens, CD19",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Humans",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Immunotherapy, Adoptive",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Lymphoma, Large B-Cell, Diffuse",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "Receptors, Chimeric Antigen",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "Treatment Outcome",
            "@weight": "b",
            "@candidate": "n"
        }
    ]},
    "language": {"@xml:lang": "eng"},
    "authkeywords": {"author-keyword": [
        {
            "@_fa": "true",
            "$": "Axicabtagene ciloleucel"
        },
        {
            "@_fa": "true",
            "$": "chimeric antigen receptor (CAR) T-cell therapy"
        },
        {
            "@_fa": "true",
            "$": "cytokine release syndrome (CRS)"
        },
        {
            "@_fa": "true",
            "$": "immune effector cell-associated neurotoxicity syndrome (ICANS)"
        },
        {
            "@_fa": "true",
            "$": "large B-cell lymphoma (LBCL)"
        }
    ]},
    "subject-areas": {"subject-area": [{
        "@_fa": "true",
        "$": "Pharmacology (medical)",
        "@code": "2736",
        "@abbrev": "MEDI"
    }]},
    "authors": {"author": [
        {
            "ce:given-name": "Karthik",
            "preferred-name": {
                "ce:given-name": "Karthik",
                "ce:initials": "K.",
                "ce:surname": "Nath",
                "ce:indexed-name": "Nath K."
            },
            "@seq": "1",
            "ce:initials": "K.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60009343",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
            },
            "ce:surname": "Nath",
            "@auid": "57211201733",
            "author-url": "https://api.elsevier.com/content/author/author_id/57211201733",
            "ce:indexed-name": "Nath K."
        },
        {
            "ce:given-name": "Kitsada",
            "preferred-name": {
                "ce:given-name": "Kitsada",
                "ce:initials": "K.",
                "ce:surname": "Wudhikarn",
                "ce:indexed-name": "Wudhikarn K."
            },
            "@seq": "2",
            "ce:initials": "K.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002620",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
            },
            "ce:surname": "Wudhikarn",
            "@auid": "37091810400",
            "author-url": "https://api.elsevier.com/content/author/author_id/37091810400",
            "ce:indexed-name": "Wudhikarn K."
        },
        {
            "ce:given-name": "Ana",
            "preferred-name": {
                "ce:given-name": "Ana",
                "ce:initials": "A.",
                "ce:surname": "Alarcon Tomas",
                "ce:indexed-name": "Alarcon Tomas A."
            },
            "@seq": "3",
            "ce:initials": "A.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60033237",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60033237"
            },
            "ce:surname": "Alarcon Tomas",
            "@auid": "57202007577",
            "author-url": "https://api.elsevier.com/content/author/author_id/57202007577",
            "ce:indexed-name": "Alarcon Tomas A."
        },
        {
            "ce:given-name": "Miguel-Angel",
            "preferred-name": {
                "ce:given-name": "Miguel Angel",
                "ce:initials": "M.A.",
                "ce:surname": "Perales",
                "ce:indexed-name": "Perales M.A."
            },
            "@seq": "4",
            "ce:initials": "M.-A.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60009343",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
                },
                {
                    "@id": "60007997",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997"
                }
            ],
            "ce:surname": "Perales",
            "@auid": "6701893624",
            "author-url": "https://api.elsevier.com/content/author/author_id/6701893624",
            "ce:indexed-name": "Perales M.-A."
        }
    ]}
}}